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ABSTRACT 
OBJECTIVES: The Appalachia region experiences excess cancer mortality and a lack 
of access to cancer care resources. There is limited research examining adjuvant 
treatment use disparities in this region. This study aims to explore adjuvant endocrine 
therapy (AET) utilization in Appalachia, and delineate the effects of access to cancer on 
AET use. 
METHODS: Female breast cancer patients were identified in cancer registries from the 
Appalachian counties in four states (KY, NC, OH, and PA) and linked to 2006-2008 
Medicare claims data. We included patients with invasive, non-metastatic, hormone-
receptor-positive breast cancer and assessed the prevalence of receiving guideline-
recommended AET. We then assessed AET adherence among those who received 
guideline-recommended AET using the Medication Possession Ratio (MPR), and 
determined non-persistence, defined as exceeding a 60-day medication gap.  We also 
used survival analyses to examine the influences of AET adherence and persistence on 
overall survival. 
RESULTS: Only 450 of the 946 eligible patients (47.6%) received guideline-
recommended AET, which was significantly associated with shorter travel time to 
receive care, dual Medicare and Medicaid eligibility, being unmarried (vs. married), and 
living in Pennsylvania (vs. Ohio). The non-adherence rate was about 31% and non-
persistence rate was 30% over an average follow-up period of 421 days. Tamoxifen, 
relative to aromatase inhibitors, was associated with higher odds of adherence (Odds 
 xviii 
 
Ratio = 2.82, p < 0.001) and a lower risk of non-persistence (Hazard Ratio = 0.40, p < 
0.001). Side effects like pain may be an important factor leading to non-adherence and 
early discontinuation. Non-adherence to and non-persistence with AET were associated 
with higher risks of all-cause mortality. 
CONCLUSIONS: In Appalachia, geographic and socioeconomic factors such as travel 
time to receive care and healthcare plan type are important elements that could 
contribute to disparities in access to adjuvant treatment, while treatment choice and 
medication-related factors may exert strong influences on AET use behaviors. 
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CHAPTER 1 
INTRODUCTION 
1.1 Background to the problem 
The Appalachian region of the United States (U.S.) covers 204,452 square miles in 420 
counties along the spine of the Appalachian Mountains.1,2 This region contains all of 
West Virginia, and portions of 12 other states: New York, Pennsylvania, Ohio, Maryland, 
Kentucky, Virginia, Tennessee, North Carolina, South Carolina, Georgia, Alabama, and 
Mississippi. Forty-two percent of the population of this region lives in rural, mountainous 
environments.2 Appalachia is much less racially diverse than the rest of the U.S.: only 
16.1% of the population is non-white.1 The population have high poverty rates (16.1% 
overall, compared to a national average of 14.3%) and low educational attainment 
rates.1 According to the Appalachian Regional Commission (ARC), 108 of 420 counties 
(25.7%) are high-poverty areas with poverty rates over 1.5 times the national average in 
the period 2007-2011.3 The regional per capita income is 16.7% lower than the U.S. 
average; in central Appalachia, it is 34.8% lower than the U.S. average.1 About 16.5% 
of Appalachian residents have less than a high school education, compared to 14.6% in 
the U.S. overall.1    
Poor access to adequate healthcare is a continuing problem in Appalachia. The 
National Cancer Institute (NCI) classifies the Appalachian region as a special population 
of interest due to significant cancer care and outcome disparities for most common 
cancers.4–6 Among Appalachian women, breast cancer is the most commonly 
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diagnosed cancer and has the second highest mortality rate following lung and 
bronchus cancer.7 In terms of early breast cancer detection and screening, the 
percentage of Appalachian women aged 40 years or older who get mammograms or 
clinical breast examinations (CBE) is significantly lower than the national average.8,9 In 
addition, Appalachian women are subject to a higher prevalence rate of modifiable risk 
factors associated with breast cancer including inadequate fruit and vegetable 
consumption, little or no physical activity, and obesity.7,8 Appalachian women are also 
less likely to receive guideline-appropriate adjuvant radiation therapy after breast 
conserving surgery (BCS),10 which raises concerns about potential disparities in the 
utilization of other recommended adjuvant treatments.  
Breast cancer mortality has declined in recent decades, but the breast cancer mortality 
decline in Appalachia has been only about half of that in the non-Appalachian regions.11 
Among the factors that are likely to contribute to cancer disparities in Appalachia, lack of 
access to adequate, effective cancer care is a critical factor. Rural residence, 
geographic isolation, lack of public transportation, underdeveloped telecommunication 
infrastructure, high poverty and unemployment rates, inadequate medical resources, a 
shortage of healthcare professionals, lower levels of educational attainment, and 
attitudinal and cultural factors in Appalachia may all result in poor access to care.9,12–14 
Currently, surgery remains the primary treatment modality for breast cancer, but recent 
marginal gains in survival may be largely attributable to the adjuvant therapy that 
usually follows primary therapy,15–17 including adjuvant radiation, chemotherapy, 
targeted therapy, and endocrine therapy. With the growing number of breast cancer 
survivors, breast cancer care should not only provide active treatment but also 
 3 
 
survivorship care such as post-treatment monitoring and risk-reducing maintenance 
behaviors.  
Oral adjuvant endocrine therapy (AET) such as tamoxifen and aromatase inhibitors 
(AIs) is a secondary prevention therapy recommended for use among hormone-receptor 
(HR) positive breast cancer survivors for a period of five to ten years to reduce 
recurrence and improve survival.18–21 Breast cancer survival disparities may also be 
partly attributable to the receipt of appropriate AET, which in turn may be related to 
patient access to care, especially in a region like Appalachia.  Additionally, patient 
adherence and persistence to AET are critical in maximizing treatment benefits; this has 
been identified as a significant issue in clinical practice, with non-adherence and non-
persistence rates as high as 59% and 73%, respectively.22,23 In all, there is increasing 
recognition in the literature that greater effort should be made to improve adjuvant 
treatment use to pursue better cancer outcomes. 
 
1.1 Need for the study 
AET is associated with lower risks of breast cancer recurrence, contralateral breast 
cancer, and death.18–21 Apart from its benefits in improving clinical outcomes, AET is 
also associated with fewer side effects or more tolerable side effects than adjuvant 
chemotherapy and increased convenience of drug administration. Based on consistent 
findings of long-term benefits, the National Comprehensive Cancer Network (NCCN) 
and the American Society of Clinical Oncology (ASCO) guidelines recommend 
extended use of AET for five to ten years among breast cancer survivors with positive 
HRs and without contraindications.24–26 Despite the long-term benefits of AET, however, 
the use of guideline-recommended AET is unsatisfactory in actual practice, especially 
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among underserved populations.27 And in spite of the importance of adherence and 
persistence to AET for the prescribed period, non-adherence and non-persistence are 
prevalent and increase with time.22,23  
AET use is related to several access-related factors, including patients’ socioeconomic 
status, out-of-pocket costs, and facility and provider types.23,27,28 However, there are no 
studies that systemically evaluate the relationship between access to cancer care and 
AET use patterns, adherence, and persistence, which leaves a significant gap in breast 
cancer treatment research. In addition, the literature examining AET use behaviors 
among breast cancer survivors in underserved regions, though warranted, is very 
limited.22 Furthermore, current research into the reasons for breast cancer outcome 
disparities in Appalachia still mainly focuses on breast cancer prevention and screening, 
as well as primary cancer treatment, and does not include adjuvant treatment use.  
To fill these gaps, we analyzed a large combined dataset to examine AET utilization and 
its relationships with access to cancer care and survival among breast cancer survivors 
in the Appalachian counties of four Appalachian states. The contribution of this study is 
to identify the effects of access to cancer resources on AET utilization and, in turn, on 
survival outcomes. The contribution is significant because the study findings will 
advance understanding of the complexity of the relationship between access to cancer 
care and AET use in Appalachia. This study also adds to the current literature about 
whether and to what extent AET adherence and persistence influence survival after 
controlling access factors. All of these contributions are informative for the design and 
development of evidence-based interventions and public health policies to improve AET 
use and reduce survival disparities in Appalachia and similar rural and underserved 
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regions. This study also demonstrates the importance of tailoring research hypotheses 
and intervention strategies for medication-use behaviors based on the characteristics of 
a specific population or geographic region. Our long-term goals are to maximize the 
benefits of breast cancer treatment, reduce breast cancer disparities, and improve 
breast cancer survival in Appalachia.    
 
1.2 Purpose of the study 
We aimed to explore the relationships between access to cancer care resources, 
adjuvant treatment use, and therapeutic outcomes among Appalachian breast cancer 
survivors. Our central hypothesis was that breast cancer patients who had better access 
to cancer care were more likely to receive appropriate adjuvant treatment and conform 
to treatment recommendations, which could lead to better therapeutic outcomes. We 
planned to test our central hypothesis by pursuing the following two specific aims: 
(1) Assess the relationship between access to cancer resources and the 
receipt of guideline-appropriate adjuvant endocrine therapy. 
Working hypothesis 1.1: Breast cancer patients who had better access to cancer care 
resources were more likely to receive guideline-appropriate adjuvant endocrine therapy. 
(2) Examine the association between access to cancer care resources and 
adjuvant endocrine therapy adherence and persistence, as well as the 
influences of AET adherence and persistence on survival. 
Working hypothesis 2.1: Among those who received guideline-appropriate adjuvant 
endocrine therapy, patients who had better access to cancer care resources were more 
likely to have better treatment adherence and persistence.  
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Working hypothesis 2.2: Among breast cancer patients who received guideline-
appropriate adjuvant treatment, those who were adherent to and persistent with their 
adjuvant treatments had a lower risk of death during the study period, after controlling 
for access to cancer care. 
 
1.3 Nature of the study 
This project was a retrospective cohort study of female breast cancer survivors who 
resided in the Appalachian counties of four states (PA, OH, KY, and NC) from January 
1, 2006 to December 31, 2008. We integrated data from multiple sources: the primary 
data sources were cancer registries from the four states and the Centers for Medicare & 
Medicaid Services (CMS) Medicare claims data. The primary outcome measures were 
AET utilization, AET adherence/persistence, and survival outcomes. The expected 
outcome of this study was a description of adjuvant treatment utilization among breast 
cancer survivors in Appalachia, the manner in which the determinants of access to 
cancer care resources impact AET adherence and persistence, and the influence of 
these factors on survival. Such outcomes may have a positive impact on future 
endeavors to improve medication use and health outcomes among breast cancer 
survivors, ultimately improving the quality of breast cancer survivorship care. 
To the best of our knowledge, this is one of few studies comprising a large, 
representative sample and substantial data to study access to care and cancer 
treatment use in Appalachia. Most of the previous studies of this size and capacity used 
data from the Surveillance, Epidemiology, and End Results (SEER) program, which 
does not include most of the Appalachian states.29 Furthermore, this study is among the 
 7 
 
first to integrate the theoretical concepts of access to care, to link them to AET 
utilization and use behaviors, and to determine their influence on cancer survival. To 
guide our study design, measures, and analyses, we utilized a new integrated 
conceptual framework based on research about access to care, cancer disparities, 
medication adherence, and health outcomes. This conceptual framework can also guide 
future research to explore medication use disparities in other rural areas and develop 
effective interventions for improving adherence to oral anticancer medications.  
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CHAPTER 2 
LITERATURE REVIEW 
To better understand how access to care impacts AET utilization in Appalachian breast 
cancer survivors, it is important to review the trajectory of breast cancer and to identify 
where AET plays a role. A good knowledge of the multilevel landscape of breast cancer 
disease course and management can help us to understand and assess decision-
making and associated behaviors of prescribers and patients, including related 
predictors and consequences. The following sections describe the relevant context of 
breast cancer care and the role of AET in it. In addition, this chapter describes the 
measurement framework of this study, which is guided by both empirical evidence about 
AET use and theoretical constructs of patient health utilization, health disparities, and 
health outcomes.  
 
2.1 Overview of female breast cancer 
2.1.1 Epidemiology and economic burden of female breast cancer 
Breast cancer is the most common cancer in women worldwide.30 This is also true in the 
U.S., where the incidence of breast cancer was 122.8 per 100,000 women in the years 
2007-2011, almost twice as high as the incidence rate of the second most common 
cancer.31 In fact, the U.S. has one of the highest incidence rates of breast cancer in the 
world.32 Fourteen percent of all new cancer cases in the U.S. are breast cancer cases, 
and 12.3% of females are diagnosed with breast cancer at some time point in their 
 9 
 
lives.33 The current five-year breast cancer survival rate in the U.S. is 89.2%, though an 
individual’s prognosis is largely influenced by the cancer stage at the time of diagnosis. 
Average five-year survival rates vary from 25% for distant stage breast cancer to 98.5% 
for local stage breast cancer. Figure 2.1 shows the trends of breast cancer incidence 
and mortality in the U.S. during the last few decades (adopted from SEER stat fact 
sheets: breast cancer).33 
  
Figure 2.1 Breast cancer incidence and mortality trends in the U.S., 1975-2011  
 
 
Adopted from SEER stat fact sheets: breast cancer33 
 
From Figure 2.1, we can see that incidence has increased overall, which is due, in part, 
to an increase in new cases diagnosed as a result of improved breast cancer screening. 
The trend seems to have stabilized over the last 10 years. The figure also shows that 
the annual reduction in the death rate was about 1.9% from 2002 to 2011, which may 
be largely attributable to advancements in breast cancer screening, care, and 
management.   
Overall, the combination of high incidence and increased survival rates leads to high 
prevalence: in the U.S., an estimated 2,899,726 women were living with breast cancer 
as of 2011.33 The breast cancer survivor population is expected to continue to grow, 
increasing awareness of the need for breast cancer survivorship care and support to 
further improve survivors’ life expectancy and quality of life. 
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It is not surprising that, globally, cancer imposes a greater economic burden, to both 
patients and to society, than any other disease; this includes the costs of productivity 
loss due to premature death and disability, as well as health expenditures.34,35 
According to a report from the National Institutes of Health (NIH), the estimated total 
annual cost of all cancers in 2009 was about $216.6 billion in the U.S., 40% of which 
was direct medical costs and 60% of which was indirect mortality costs.35 A major 
proportion of direct medical costs covered cancer treatments. Due to the high costs 
associated with cancer treatments, insurance status and coverage play a very critical 
role in access to and utilization of these treatments, which leads to disparities in cancer 
care quality and outcomes. In addition, the financial costs associated with cancer are 
expected to grow faster than overall healthcare expenditures because, in an aging 
population, more people are at increased risk of cancer, and because more novel, 
advanced, and expensive cancer treatments are now included in standard cancer 
care.36  
With regard to direct medical expenditures, female breast cancer is the most expensive 
type of cancer in the U.S.37 It was associated with $16.5 billion in healthcare 
expenditures in 2010. Costs are generally highest in the first year after diagnosis (initial 
phase) and the last year of life (last phase), following a “U” shape.36,38 Breast cancer 
care expenditures also depend on cancer staging; it is more expensive to treat late-
stage breast cancer than to treat early-stage breast cancer.39,40 If we further examine 
indirect costs associated with productivity loss due to premature death or disability, 
female breast cancer is the third most costly type of cancer worldwide and the second 
most costly in the U.S. 34,36 The indirect costs associated with female breast cancer 
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were estimated at $12.1 billion in the U.S. in 2005.41 Given this significant economic 
burden, there is a need to develop and employ cost-effective treatment strategies to 
reduce recurrence and improve survival rates. 
 
2.1.2 Breast cancer care trajectory  
Figure 2.2 depicts a simplified overview of the breast cancer care trajectory (Adapted 
from “From Cancer Patient to Cancer Survivor: Lost in Transition (2005)”).42 A typical, 
hypothetical patient, Ms. A, shows something suspicious during a screening test or 
presents signs or symptoms. She is given diagnostic tests, which may include an 
imaging test or biopsy. Ms. A is diagnosed with breast cancer and the stage is 
confirmed. If she is diagnosed with metastatic breast cancer with a poor prognosis, she 
is unlikely to be cured and palliative therapy (without the intention to cure) can be 
offered to her. On the other hand, if her prognosis is better and she is willing to receive 
active primary treatment, one of two things happens: either the treatment works and she 
is cancer-free or the treatment fails. In the latter case, she can either receive other 
treatment options or palliative care. If Ms. A survives her primary treatment and 
becomes cancer-free, she can also receive survivorship care with the goal of keeping 
her healthy and reducing the risks of breast cancer recurrence, metastasis, and death. 
The survivorship phase is also where AET comes into play, which is the focus of our 
research. But before we describe our research, we will briefly introduce several 
important components of breast cancer care.   
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  Figure 2.2 Breast cancer care trajectory  
 
 
  Adapted from “From Cancer Patient to Cancer Survivor: Lost in Transition (2005)”42 
 
 
2.1.2.1 Breast cancer screening, diagnosis and staging 
Assessing breast cancer risks and conducting screenings can both significantly improve 
survival rates by detecting breast cancer early and preventing treatment delay. There 
are three classic screening modalities: breast self-examination, clinical breast 
examination (CBE), and mammography. Breast self-examination tends to be 
discouraged now due to questions about its effectiveness.43 Mammography, a powerful 
tool that is able to detect the smallest cell mass size at 1mm, has been shown to reduce 
breast cancer mortality by 15%.44,45 Most current guidelines in the U.S. therefore 
recommend that women over 40 get mammograms annually or biennially. However, its 
role in screening is not uncontroversial: issues of safety, false positive rates, and costs 
with regard to its application as a screening tool in the large general population are all 
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concerns. CBE provides a unique complement to imaging tests, especially given that 
mammography still misses 10% -15% of palpable masses. In addition, CBE benefits 
those patients who are not yet 40; therefore, most current screening guidelines in the 
U.S. recommend CBE for women aged 20-39 every one to three years.43 
Diagnostic examinations include diagnostic mammography, biopsies, and supplemental 
imagining views such as ultrasounds and magnetic resonance imagining (MRI) scans. 
The majority of breast cancer cases (>90%) are identified based on abnormal 
mammograms.46 After reviewing diagnostic mammogram results, which have a higher 
sensitivity and lower specificity than screening mammogram results, the radiologist uses 
the American College of Radiology (ACR) BI-RADS (Breast Imaging Reporting and 
Data System) final diagnostic assessment categories to standardize the report of 
mammographic findings and provide recommendations for future management.47  
Two important breast cancer receptor tests can affect treatment strategy choices: 
hormonal receptor tests and human epidermal growth factor 2 (HER2) receptor tests. 
Estrogen receptor (ER) and progesterone receptor (PR) overexpression are prognostic 
factors for newly diagnosed invasive breast cancer.48 The presence of ER or PR in >1% 
of the cancer cells indicates a positive result.48 The recurrence rate is significantly 
higher for ER-negative cancer than ER-positive cancer.49 ER and PR tests are 
warranted because ER and/or PR positive patients may be eligible for endocrine 
therapy as neoadjuvant (pre-primary treatment) or adjuvant treatments. HER2 receptor 
overexpression, a marker of poor prognosis, occurs in about 15%-20% of breast cancer 
cases.50 The value of this test lies in predicting candidates for HER2-directed therapy, 
since positive HER2 receptors are the target of HER2-directed therapy.  
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Clinicians use cancer staging information to determine the size and location of the 
tumor, which may help them make a prognosis, guide treatment plan development, and 
facilitate communication with patients.51 Table 2.1 illustrates breast cancer staging in 
detail (Adopted from American Joint Committee on Cancer [AJCC] breast cancer 
staging, 7th edition).52 Based on the TNM staging system, five-year survival rates are 
about 95%, 85%, 70%, 52%, 48%, and 18% for patients presenting with stage I, IIA, IIB, 
IIIA, IIIB, and IV breast cancer, respectively.53 
 
Table 2.1 Breast cancer staging  
 
Stage T category N category M category 
Stage 0 Tis N0 M0 
Stage IA T1 N0 M0 
Stage IB T0 N1mi M0 
T1 N1mi M0 
Stage IIA T0 N1 M0 
T1 N1 M0 
T2 N0 M0 
Stage IIB T2 N1 M0 
T3 N0 M0 
Stage IIIA T0 N2 M0 
T1 N2 M0 
T2 N2 M0 
T3 N1 M0 
T3 N2 M0 
Stage IIIB T4 N0 M0 
T4 N1 M0 
T4 N2 M0 
Stage IIIC Any T N3 M0 
Stage IV Any T Any N M1 
Descriptions: 
 Tis: carcinoma in 
situ 
T0: no evidence 
of primary tumor 
T1: tumor 
size≤20mm 
T2: 
20mm<tumor 
size≤50mm 
T3: tumor 
size >50mm 
T4: tumor of any 
size with direct 
extension to the 
chest wall and/or 
to the skin  
N0: no regional lymph node metastases 
N1mi: lymph nodal  micrometastases 
N2: metastases in ipsilateral level I, II axillary lymph nodes that 
are clinically fixed or matted; or in clinically detected ipsilateral 
internal mammary nodes in the absence of clinically evident 
axillary lymph node metastases 
N3: Metastases in ipsilateral infraclavicular (level III axillary) 
lymph node(s) with or without level I, II axillary lymph node 
involvement; or in clinically detected ipsilateral internal mammary 
lymph node(s) with clinically evident level I, II axillary lymph node 
metastases; or metastases in ipsilateral supraclavicular lymph 
node(s) with or without axillary or internal mammary lymph node 
involvement 
M0: no 
evidence of 
distant 
metastases 
M1: distant 
detectable 
metastases 
Adapted from the American Joint Committee on Cancer [AJCC] breast cancer staging, 7
th
 edition
52
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2.1.2.2 Survivorship care  
According to the most recent NCCN survivorship guidelines,54 survivorship care for 
patients who have survived primary cancer treatment and are in remission should 1) 
monitor and prevent cancer recurrence, metastases, and new cancer; 2) evaluate long 
term physical and psychological effects; 3) deal with the consequences of cancer and 
treatment; and 4) coordinate care including primary care providers and specialists. The 
discussion of survivorship care may also be appropriate for patients with metastatic 
cancer. For breast cancer survivors, the ASCO recommends physical examinations, 
mammography, and pelvic examinations.55 Adjuvant therapy including adjuvant 
chemotherapy and AET may also be administered to breast cancer survivors to prevent 
breast cancer recurrence, contralateral breast cancer, and death. However, these 
treatments are associated with increased risk of side effects such as infertility, 
osteoporosis, and symptoms of estrogen deprivation, cardiovascular diseases, and 
weight gain, though prevention and management strategies related to these side effects 
also exist. Pain management for patients experiencing pain from cancer or treatment is 
crucial and involves different treatments for various types of pain. Women who received 
axillary dissection and/or radiation therapy may experience arm lymphedema, which 
can be managed by massage and exercise, elastic compression garments, and 
complex decongestive therapy. All survivors are encouraged to maintain adequate 
levels of physical activity and healthy lifestyles, especially in the case of fatigue. In 
addition, regular screenings for psychological distress and depression are important, as 
are appropriate referrals and interventions. Finally, genetic counseling may also be 
conducted to determine the risk to family members.   
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2.2 Managing breast cancer 
2.2.1 Breast cancer treatment options 
In this section, we discuss current available treatment options for breast cancer. Not all 
women with breast cancer receive all of these treatments, and the order of treatments 
varies across individuals.50 Surgery is the primary treatment in most non-metastatic 
breast cancer cases, but when a woman is not eligible, other primary treatment options 
may be available. Neoadjuvant treatment precedes primary treatment. For example, 
chemotherapy can be used as a neoadjuvant treatment to reduce the size of a tumor 
and facilitate surgery. Adjuvant treatment follows primary treatment. 
 
2.2.1.1 Surgery 
The breast conserving surgery (BCS) and mastectomy are the two most common breast 
cancer surgeries. A BCS can be a simple lumpectomy, with the tumor mass and some 
surrounding normal tissue removed, or a quadrantectomy, which is like a lumpectomy 
plus a partial mastectomy. A mastectomy, on the other hand, involves removing a large 
part or the whole breast.50 In 1990, the NIH consensus report advised that BCS followed 
by radiation was a safe and effective choice for early-stage breast cancer based on the 
evidence of a few well-known randomized clinical trials (RCTs).56–58 And for the next two 
decades, follow-up studies showed non-inferior outcomes for BCS in combination with 
radiation compared to mastectomy.59,60 In addition, radiation was critical in marginally 
decreasing breast cancer deaths. Recently, however, there have been some changes in 
clinical recommendations on whether to administer radiation after BCS for HR-positive 
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stage I breast cancer patients; specifically, endocrine therapy is an alternative to 
radiation after BCS. 61–63 
In addition, lymphadenectomy is a procedure for checking whether cancer has spread 
to the lymph nodes and to remove lymph nodes.50 There are two types of 
lymphadenectomies: sentinel lymph node biopsy for the further examination of lymph 
nodes if no signs of cancer are present in the first test, and axillary lymph node 
dissection for the removal of all lymph nodes under the armpit in cases of malignant 
lymph nodes. 
 
2.2.1.2 Radiation therapy  
Radiation therapy, a procedure that uses high-energy rays or particles to kill remaining 
cancer cells after surgery, is considered a local adjuvant therapy because it usually 
follows surgery and targets local, specific areas such as the breast.50 Radiation can also 
be focused on just the original tumor site instead of the whole breast, which is called 
partial breast irradiation. Currently, there are two types of radiation: external beam 
radiation therapy (EBRT), which delivers radiation from a machine outside the body 
(externally), and brachytherapy, which places flexible plastic catheters with radioactive 
material into or around the original tumor (internally). Radiation therapy often follows 
BCS to destroy remaining cancer cells. If cancer cells spread to lymph nodes, radiation 
therapy can be used to target these affected areas as well. 
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2.2.1.3 Systemic therapy 
Breast cancer cells have the ability to spread cancer to other parts of the body. The 
drugs that have systemic effects to treat or prevent this are called systemic therapy and 
can include chemotherapy, endocrine therapy, targeted/biologic therapy, or a 
combination of these agents. Systemic therapy is usually an adjuvant therapy, but it is 
sometimes used as a neoadjuvant therapy for shrinking the tumor before surgery. 
 
2.2.1.3.1 Chemotherapy 
Chemotherapy plays an important role in the management of invasive, non-metastatic 
breast cancer and can also be used to help control metastatic cancer. A single agent or 
a combination of several drugs can be used. Chemotherapy usually targets certain 
phases of the cell cycle, so it not only intervenes in the growth of cancer cells but also 
damages normal cells. It may cause side effects, some of which greatly impact quality 
of life. Chemotherapy generally has very narrow therapeutic windows; very careful 
planning is required for dosing and scheduling.64 To balance effectiveness and safety 
and to give normal cells a recovery period, chemotherapy is administered at regular 
intervals called cycles.64 Cycles vary depending on the chemotherapy used. For 
instance, cycles are often 14, 21, or 28 days long with treatment days followed by 
treatment breaks. The number of cycles administered is based on tumor characteristics 
and overall patient health. 
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2.2.1.3.2 Targeted therapy 
Traditional chemotherapy can damage normal cells in the process of killing cancer cells. 
Targeted therapy is specific to cancer cells and produces fewer and less severe side 
effects. It often targets carcinogenesis, a process in which genes change and can cause 
cancer. HER2-directed therapy targets the overexpressed HER2 protein, which is 
present in approximately 20% of breast cancer cases.65 The therapy includes 
trastuzumab (herceptin), a recombined DNA-derived humanized monoclonal antibody 
that inhibits the growth of tumor cells by attaching to the HER2 protein. Trastuzumab is 
a commonly used adjuvant or neoadjuvant therapy for HER2-positive breast cancer. In 
addition, Everolimus (Afinitor®), another targeted therapy for breast cancer, is a FKBP-
12 complex that attaches and blocks the mammalian Target Of Rapamycin (mTOR) and 
its substrate. It can be combined with exemestane to treat advanced cases of HR-
positive and HER2-negative breast cancer after letrozole or anastrozole has failed.  
 
2.2.1.3.3 Endocrine therapy 
Endocrine therapy is a critical part of standard adjuvant therapy for invasive, HR-
positive, non-metastatic breast cancer. Different types of endocrine therapy work 
through distinct mechanisms to treat breast cancer.66 One mechanism blocks estrogen, 
while the other reduces estrogen levels. Drugs associated with the first mechanism 
include tamoxifen, toremifene (Fareston®), and fulvestrant (Faslodex®). Among them, 
tamoxifen and toremifene belong to the drug class called selective estrogen receptor 
modulators (SERMs). The second mechanism uses ovarian suppression/ablation and 
aromatase inhibitors (AIs). Ovarian suppression/ablation is indicated for premenopausal 
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women and works either by removing the ovaries that are the main source of estrogen 
or by using luteinizing hormone-releasing hormone (LHRH) agonists such as 
goserelin (Zoladex®) or leuprolide (Lupron®).66 So far, the benefits of combining ovarian 
suppression/ablation with other systemic adjuvant therapies remain unclear, so it is only 
recommended, alone or in combination, if the patient is not eligible for other systemic 
therapies or cannot tolerate the side effects.67 This particular study focuses on the most 
commonly used oral endocrine therapy: tamoxifen and aromatase inhibitors (AIs). 
 
Tamoxifen  
Tamoxifen is a SERM that competes with estrogen on HR-positive breast cancer. It has 
been the gold standard endocrine therapy for HR-positive breast cancer for decades. In 
line with the latest research, the ASCO and NCCN clinical practice guidelines 
recommend tamoxifen as the first-line systemic adjuvant therapy for HR-positive 
invasive breast cancer treatment for up to 10 years.24,25 It can also be used as 
neoadjuvant therapy. The Early Breast Cancer Trialists' Collaborative Group’s 
(EBCTCG) meta-analysis of 20 clinical trials with a total sample of 21,457 patients 
compared the five-year use of tamoxifen as AET with no tamoxifen in the treatment of 
ER-positive breast cancer.68 After controlling for age, lymph node status, tumor size and 
grade, and the use of chemotherapy, the study found that tamoxifen significantly 
decreased the 15-year risk of breast cancer-specific mortality by about 30% and 
reduced the 15-year risk of recurrence rate by 39%. More specifically, it lowered the 
risks of local recurrence by 46%, contralateral breast cancer by 38%, and distant 
recurrence by 37%. In addition, the recent ATLAS (Adjuvant Tamoxifen Longer Against 
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Shorter) trial,69 found that 10-year use of tamoxifen compared to 5-year use was 
associated with an absolute mortality reduction of 2.8% (p = 0.01). Extended use of 
tamoxifen can also reduce the risks of breast cancer recurrence69–71 and contralateral 
breast cancer.69  
Due to the long history of tamoxifen use, its side effects, risks, and impacts on quality of 
life have been relatively well studied. Common side effects include menopausal 
symptoms (e.g., hot flashes and vaginal changes).67 Rare but severe side effects 
involve pulmonary embolism (PE), deep venous thrombosis (DVT), and endometrial 
cancer. The risks of ischemic heart disease remain controversial.25,67 Even though 
some adverse effects such as menopausal symptoms may be bothersome to patients, 
tamoxifen use does not negatively impact overall quality of life.25,67  
 
Aromatase inhibitors (AIs) 
Three AIs are available: anastrozole, letrozole, and exemestane. AIs are recommended 
as AET for postmenopausal women with HR-positive breast cancer.24,25,67 The EBCTCG 
meta-analysis of AIs vs. tamoxifen found that AI had a lower breast cancer recurrence 
rate than tamoxifen but showed no significant difference in mortality after 5 years of use 
72; switching from tamoxifen to AI after two to three years (for a total of five years of AET) 
was associated with an absolute 3.1% recurrence rate decrease and a 0.7% decrease 
in breast cancer-specific mortality, compared to the use of only tamoxifen for 5 years. 
Another meta-analysis of RCTs also suggested that switching therapy (from tamoxifen 
to AI) was preferable in terms of the increase in overall survival.73 Emerging evidence 
also supports the use of AIs as initial therapy for postmenopausal women.67 In terms of 
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effectiveness and safety, AIs are considered equivalent to tamoxifen as an initial 
therapy for postmenopausal women.24,26 Currently, there is no evidence suggesting the 
advantages of AIs or AI and LHRH agonists combination therapy over tamoxifen and 
ovarian suppression/ablation for premenopausal women.67 There are also no data to 
support the extended use of AI (>5 years) in postmenopausal women.25 
Generally, AIs have a different side effect and risk profile than tamoxifen. Common side 
effects of AIs include osteoporosis, musculoskeletal and joint pain, and cardiovascular 
events such as hypertension and hypercholesterolemia. While overall quality of life may 
not be significantly impacted, physical function may be impaired due to musculoskeletal 
and joint pain.25 AIs are associated with a lower risk of PE/DVT but a higher risk of 
cardiovascular disease than tamoxifen,74 and a higher rate of bone fracture compared to 
a placebo.75 For postmenopausal women, drug choice depends on effectiveness but 
also on patients’ tolerance of side effects and their preferences, especially when the 
drug must be used for an extended time period. If patients cannot tolerate side effects 
or if side effects are not carefully monitored and well managed, patient adherence to 
and persistence with AET may be jeopardized, which could further impact the 
effectiveness of the therapy.  
 
The sequence and optimal duration of tamoxifen and AIs  
Recommendations from the NCCN and the ASCO regarding AET use in HR-positive, 
invasive, non-metastatic breast cancer patients are generally consistent.24,25 The choice 
of drug is based on menopausal status: AIs are indicated for postmenopausal women 
only. The optimal durations for tamoxifen and AI are ten and five years, respectively. So 
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for a woman who is pre- or peri-menopausal or of unknown menopausal status, 
tamoxifen can be initiated for five years. Later, if the patient becomes postmenopausal, 
she can either continue with tamoxifen for a total of ten years or switch to AI for five 
more years. On the other hand, for postmenopausal women, either AI or tamoxifen can 
be initiated as AET for five and ten years, respectively. If a patient cannot tolerate the 
side effects during these years, she can switch to the other AET. She can also start with 
tamoxifen or AI for two to three years and then to switch to the other AET for five 
additional years.  
In all, treatment choices for breast cancer are based on cancer staging, as well as 
tumor characteristics such as HR positivity and HER2 status. According to current 
guidelines, AET is recommended in all cases of HR-positive, invasive, non-metastatic 
breast cancer. Adjuvant chemotherapy is recommended in more advanced cases, but 
not for women older than 70 due to a lack of evidence about its effectiveness in these 
patients. The addition of trastuzumab is recommended for HER2-positive breast cancer. 
 
2.3 Breast cancer disparities 
Disparities in cancer survival involve interactions between multiple factors at both the 
individual and healthcare system levels. Some factors, like genetic risks, are inherent 
and hard to change, while some factors like health behaviors, cultural beliefs, and 
health practices are modifiable. These factors can influence every stage of breast 
cancer care, from prevention to survivorship and palliative care. Here we discuss some 
important disparities in the U.S. breast cancer patient population. 
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Racial/ethnic disparities 
Black women have the highest breast cancer mortality rate of any racial group in the 
U.S., and this disparity has persisted over time, although the gap has narrowed 
slightly.33 From 1975 to 2010, the 5-year survival rate among white females with breast 
cancer increased from 75.6% to 91.8%, while for black women, it rose from 62.0% to 
80.0%.76 The mortality gap may reflect the fact that black women have a higher 
likelihood of receiving a late-stage diagnosis relative to white women (45% vs 35%).77 
Because black women also tend to be younger at diagnosis,78 they are more likely to 
have aggressive tumors with a poor prognosis. Furthermore, this disparity in survival 
still exists after controlling for clinical factors, socioeconomic status (SES), and primary 
treatment.79 Livaudais et al (2013) used self-reported measures to explore another 
possible explanation for the racial/ethnic difference in survival: whether racial disparities 
exist in the use of adjuvant therapy.80 However, they found no significant differences in 
the use of adjuvant therapy by race or ethnicity. Silber et al. (2013) also suggested that 
differences in breast cancer treatment explained only 0.81% of the 12.9% difference in 
survival rates by race.81 Social or cultural factors may also exacerbate the problem 
including poor access to care; greater perceived barriers; inadequate knowledge; and 
misbeliefs about screening, treatment, and follow-up care.82 The contributions of these 
factors may be more significant to the racial/ethnic disparities in survival than biological 
factors or prognosis based on tumor characteristics.83,84 
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Socioeconomic disparities 
Socioeconomic disparities, measured by economic status, level of educational 
attainment, or health insurance, in breast cancer care and outcomes also remain 
prevalent. For the general population of female cancer patients, low SES was 
associated with a 3% higher death rate relative to high SES.84 For breast cancer, in 
particular, SES may influence almost all aspects of care, from prevention to end-of-life 
care. Significant SES disparities have existed in mammography screening rates over 
the decades; the disparities in mammography use increased by 161% from 1987 to 
2004.85 The percentage of women diagnosed with early-stage breast cancer in 
economically competitive census tracts was higher than those in distressed census 
tracts (67% vs 59%, respectively).84,86 Uninsured patients or patients with public 
insurance were also more likely to be diagnosed with late-stage breast cancer and to 
have worse survival outcomes than those with private insurance.87,88 Compared to fee-
for-service (FFS) plans, capitated health insurance plans seemed to provide higher 
quality cancer care and better clinical outcomes including the reduced likelihood of late-
stage diagnosis89 and increased likelihood of receiving HER2 testing.90 Moreover, 
breast cancer patients living in high-poverty areas were much less likely to receive BCS 
and radiation compared to their counterparts in low-poverty areas.63 Bradley et al 
(2002)91 also argued that SES might account for most of the racial/ethnic differences in 
breast cancer survival. Their study population lived in the Metropolitan Detroit area, 
which had a good representation of minority and economically distressed communities. 
The researchers found no evidence of racial disparities after controlling for SES but 
found that low SES was related to greater likelihood of late-stage diagnosis, unfavorable 
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primary treatment choices, and death. A study among Medicare enrollees in Alabama 
made similar conclusions.92 In addition, SES might also be related to the biological and 
prognostic characteristics of breast cancer, such as ER status and obesity.93  
 
Healthcare system-level disparities 
Variations in physicians’ practice may also account for disparities in patients’ health and 
cancer survival. Physicians process and synthesize complex information to interpret 
patients’ presentation of signs and symptoms and to make clinical decisions. 
Consciously or unconsciously, they not only rely on patients’ clinical status and 
prognosis but also social and economic factors such as health insurance, race/ethnicity, 
and SES, as well as cognitive and behavioral factors such as confidence in 
communication, intention to adhere to clinical recommendations, and patient 
preferences.84,94 Physicians who treat more minority patients are less likely to 
recommend mammography screening or promote immunizations for elderly patients.95 
In addition to patients’ features, physicians’ own characteristics can influence their 
practice patterns considerably; these include education, training, experience, beliefs, 
cultural competence, communication capability, and style, as well as accessibility and 
availability.94 For example, physicians who graduated from medical school between 
1984 and 1988 were more likely to prescribe guideline-concordant endocrine therapy to 
patients with non-metastatic breast cancer than those who graduated after 1989,63 
which might reflect the emergence in the late 80s of literature on the benefits of 
endocrine therapy. Moreover, external environmental factors may also influence 
physicians’ practice, including physician incentives, reimbursements, medical resources, 
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practice guidelines, and federal and local policy. According to a study by Anderson et al 
(2014), physicians at Commission on Cancer (CoC) accredited facilities, for instance, 
were more likely than other physicians to provide guideline-concordant treatments for 
patients with non-metastatic breast cancer.96  
Cancer care calls for adequate medical resources, sophisticated technology, advanced 
and specialized practice, and communication and coordination across various settings 
and healthcare providers. The limited real-world supply of resources means that not 
every eligible cancer patient can receive optimal cancer care. System-level disparities 
depend, in part, on the features of the healthcare system including facility specialty, size, 
case volume, and quality of care. It is well recognized in the literature that treatment 
facilities with a larger volume of complicated procedures and a higher level of 
specialization such as American College of Surgeons-approved or NCI-designated 
cancer centers were associated with better cancer outcomes.97–101 These types of 
facilities tend to be concentrated in more economically competitive, non-rural areas, 
which can result in geographic disparities in medical resource allocation and cancer 
outcomes.40 Furthermore, patients may have to travel longer distances to these high-
volume facilities and designated cancer centers, partly because oversight agencies and 
insurance providers attempt to move complicated cancer care to these types of 
facilities.102  
In all, the effects induced by the abovementioned disparities may interact, leading to 
geographic differences in breast cancer care and outcomes. In other words, geographic 
disparities are a consequence of system-level characteristics such as the geographic 
distribution of medical resources along with the social, economic, and cultural 
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segregation of the population. Appalachian is a good example of a region in which 
significant cancer disparities exist. In the next section, we discuss disparities specific to 
Appalachia. 
 
2.4 Breast cancer in Appalachia 
The NCI has designated the Appalachian region as a special population of interest due 
to substantial cancer disparities for most leading cancers, including female breast 
cancer.4–6 Nevertheless, the Appalachian cancer patient population is still not well 
studied. Most of the epidemiologic data on breast cancer given above are based on the 
SEER data, which only included cancer registries in two of the thirteen Appalachian 
states, Georgia and Kentucky.29   
 
Incidence and mortality 
Among Appalachian women, breast cancer is the most diagnosed cancer and the 
second leading cause of cancer death following lung and bronchus cancer.7 The 
average annual female breast cancer incidence in the Appalachian counties in six 
states (NY, KY, WV, OH, PA, VA) was 117.1 per 100,000 females in 2002-2006, which 
was lower than the incidence in the non-Appalachian counties in these states (123.5 per 
100,000 females). However, the incidence of late-stage breast cancer at diagnosis was 
higher in the Appalachian region than the non-Appalachian region,103,104 which may be 
partially attributable to the lack of access to care in Appalachia, including a lack of 
diagnostic doctors and mammography centers and area social deprivation.5,105  
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In general, breast cancer mortality in the thirteen Appalachian states was about 7% 
higher than in the other thirty-seven states (p < 0.05).106 But there was no significant 
difference in breast cancer mortality between the Appalachian counties and non-
Appalachian counties in these thirteen Appalachian states. Breast cancer mortality in 
the U.S. has declined in recent decades, but the Appalachian region has not 
experienced a comparable decline.11 For example, the decline of breast cancer mortality 
over the period from 1969 to 2007 in Appalachian counties was only about half that of 
the non-Appalachian counties in the Appalachian states (17% vs 30%).11 
 
Risk factors, screening and treatment 
The Appalachian region has a higher prevalence of modifiable risk factors associated 
with breast cancer such as inadequate fruit and vegetable consumption, no physical 
activity, and obesity.7,8 In terms of breast cancer early detection and screening, the 
percentage of Appalachian women over 40 who get mammograms or CBE is 
significantly lower than in the rest of the U.S.8,9 A patient self-reported study in West 
Virginia found that having health insurance and reliable transportation was significantly 
associated with better adherence to mammography screening guidelines.107 Likewise, 
the findings of another qualitative study suggested that common barriers to screening 
were inadequate individual and community resources, negative attitudes or lack of 
knowledge, and competing demands.108 
There are considerable breast cancer treatment disparities between Appalachia and the 
rest of the country. First, regarding primary surgery choice, the Appalachian region had 
a much higher rate of mastectomy than the national average (45.9% vs 37.0%).10 In 
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addition, Appalachian women received guideline-appropriate radiation therapy after 
BCS at a lower rate than other American women.10,109 In a study in North Carolina, 
Wheeler et al (2014)110 found that urban/rural residence and travel distance to the 
radiation center could predict whether or not patients received radiation therapy.  
 
2.5 Medicare Part D 
Because this study focuses on Medicare enrollees, particularly on those receiving Part 
D, this section briefly reviews the Medicare program. Medicare is a federal health 
insurance program that covers medical costs for the elderly and disabled. Medicare Part 
A is a hospital insurance program that covers inpatient services, home care services, 
nursing home services, and mental health services. Part B provides supplementary 
medical insurance benefits, which cover physician services, medical equipment and 
supplies, and outpatient services.111 Part C, also called the Medicare Advantage 
program, provides enrollees with Medicare benefits through private insurance. Part C 
enrollees choose one or some combination of three types of healthcare plans: a 
coordinated care plan, a medical savings account (MSA)-based plan, or a private FFS 
plan.111 Part D is a voluntary prescription drug benefit program launched in 2006; Part A, 
B, and C beneficiaries are eligible for Part D benefits. The implementation of Medicare 
Part D has reduced cost-related drug non-adherence.112 
Prior to Part D implementation, Medicare Parts A and B covered most cancer drugs. 
After the implementation, oral cancer drugs including AET and anti-nausea drugs were 
newly covered under Part D instead of Part B. Part D enrollees generally receive their 
prescription drug benefits through private prescription drug plans (PDPs).111 Under the 
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standard prescription drug coverage plan that most Part D enrollees first pay an annual 
deductible, then pay 25% coinsurance for their total drug costs until they reach an initial 
coverage limit. Between the coverage limit and an out-of-pocket threshold, the “donut 
hole,” they pay 100% of total drug costs. Above the “donut hole,” enrollees receive 
catastrophic coverage so that they only make a small copayment and pay 5% 
coinsurance. The Patient Protection and Affordable Care Act (PPACA) reduced 
beneficiary spending in the “donut hole” by providing a rebate of $250 (in 2010 only), 
increasing discounts for both generic and brand-name drugs, and expanding coverage 
of brand-name drugs. The ultimate goal is to close the “donut hole” by 2020.  
Low-income Medicare beneficiaries may be eligible for additional subsidies. More than 6 
million beneficiaries are “dual eligible” for both Medicare and Medicaid.113,114 The dual-
eligible population is generally vulnerable and tends to have significant medical care 
needs. Dual-eligible enrollees qualify for both Medicare and Medicaid because they are 
disabled or blind, aged, and meet the Medicaid income and asset requirements.114 
Compared to Medicare-only beneficiaries, they are more likely to be either much older 
or much younger, to be in fair to poor health, to have chronic and severe health 
conditions, and to be economically distressed.114 Dual-eligible individuals are 
automatically enrolled in Part D drug plans and they do not pay monthly premium or 
deductibles.115 Many states’ Medicaid plans also help with copayments or out-of-pocket 
expenses for drugs not included in the Medicare Part D formulary. In addition, many 
states developed contingency plans during the rollout of Plan D to help dual-eligible 
enrollees obtain drug coverage through Medicaid before they were able to access to 
Part D drug benefits.113 The series of benefits that dual-eligible enrollees receive may 
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reduce the financial burden of accessing, utilizing, and adhering to medication, which 
may improve their health outcomes. Furthermore, low-income Medicare beneficiaries 
who are not eligible for Medicaid may receive additional premium subsidies based on 
their resource or asset levels.115  
 
2.6 Adjuvant Endocrine Therapy (AET) use 
2.6.1 Endocrine therapy use pattern among American women with breast cancer 
In U.S. clinical practice settings, the percentage of female breast cancer patients who 
receive tamoxifen or AI ranged from 58% to 88%, depending on study time, study 
population characteristics (e.g., age, menopausal status, HR status, residence location), 
and study methods.27,63,116–120 Tamoxifen has been widely used in the adjuvant setting 
that is given after primary treatment, especially before the approval and emerging use of 
AI among postmenopausal women. Data collected via medical reports and phone 
interviews in the 1990s showed that, nationwide, 65% to 86% of women with breast 
cancer used tamoxifen.118–120 None of those studies examined the Appalachian breast 
cancer patient population specifically.  
Since 2000, with the approval of more and more AIs, data on AI use have become 
available and a growing body of literature has begun to use pharmacy claims data to 
examine both tamoxifen and AI use in the adjuvant setting. A study of 1,491 North 
Carolina Medicaid enrollees with breast cancer in 1998-2002 found that 64% of them 
received either tamoxifen or AI, a rate that increased to 70% among women with HR-
positive breast cancer.27 The same study found that tamoxifen was much more 
frequently prescribed than AI, at 88% vs. 12% of that population, respectively. Another 
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2000-2005 study examined 2,207 female breast cancer patients enrolled in a non-profit 
commercial health plan in Massachusetts and found that only 58% received AET within 
12 months after diagnosis.117 Of those who did, 54.6% received tamoxifen only, 25.1% 
received AI only, and the rest switched between the drug classes. This differed from 
other studies in that the eligible women were new AET users, and the use of AET was 
limited to one year following diagnosis, which may partly explain the low rate of AET use 
in this population. In another study, Riley et al (2011) used SEER data and Medicare 
Part D claims data from May 2006 to December 2007 to study a nationwide Medicare 
population with Part D benefits.116 Seventy-four percent of the 15,542 Medicare 
enrollees with HR-positive breast cancer used AET; fifty-two percent of the total 
population received AIs and twenty-two percent of them obtained tamoxifen.  
These reports showed a trend of increasing AI use in the past decade. It is also 
noteworthy that the SEER data may well represent the general U.S. cancer patient 
population but not the Appalachian cancer patient population since they only included 
two of the thirteen Appalachian states, Georgia and Kentucky, and did not focus 
particularly on the Appalachian counties.29 One of the few Appalachian-focused breast 
cancer treatment studies so far, Kimmick et al (2014),63  revealed that almost 76% of 
Appalachian women with HR-positive breast cancer received either tamoxifen or AI 
within one year after diagnosis. But based on the study design, these AET users may 
not have been new users, and it is unclear whether tamoxifen and AIs were used for 
other purposes such as chemoprevention or neoadjuvant therapy, or for metastatic 
cases.  
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Two factors were consistently related to the receipt of AET: age at diagnosis and cancer 
staging. Women diagnosed between the ages of 65 and 74 were more likely to receive 
AET, as were women with more advanced breast cancer.63,116,119 In addition, Kimmick 
et al (2009) found that unmarried women were more likely than married women to 
receive AET (Odds Ratio [OR] =1.82, p < 0.001).27 Other factors associated with AET 
use included number of co-administered medications,27 breast cancer primary treatment 
used,27,116 type of treatment facility,27 provider’s medical school graduation year,63 and 
patient’s physical function and ability to communicate.119 
 
2.6.2 Outcomes associated with AET use 
This section describes the evidence that exists for outcomes associated with AET use. 
A 13-year retrospective cohort study of 1,962 women with non-metastatic breast cancer 
in the Netherlands found that adherence to tamoxifen (Medication Possession Ratio 
[MPR] ≥ 80%) was associated with a 26% reduced risk of a recurrent breast cancer 
event, after adjusting for other clinical and treatment characteristics .121 Furthermore, 
poor adherence to tamoxifen (MPR < 80%) was also significantly related to an increase 
in all-cause mortality (Hazard Ratio=1.10, 95% CI = 1.001–1.21) for both HR-positive 
and HR-negative breast cancer cases; among women with HR-positive breast cancer 
only, the risk of all-cause mortality became greater (Hazard Ratio=1.13, 95% CI = 1.01 
– 1.26). In a large claims data study of 8,769 women enrolled in a private health plan in 
Northern California, Hershman et al (2011) found that non-adherence (MPR < 80%) to 
either tamoxifen or AI was associated with a 49% higher risk of all-cause mortality (p < 
0.0001).122 When non-adherence was defined as MPR < 60%, the risk of all-cause 
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mortality associated with non-adherence to AET increased from 1.49 to 3.71 (p < 
0.0001). Another study in North Carolina Medicaid enrollees, however, did not find a 
significant relationship between adherence to AET and either breast cancer recurrence 
or breast-cancer-specific survival.123 The inconsistent results found in this study 
compared to previous ones may result from the smaller sample size (N = 857), the 
population’s demographic and diagnostic characteristics (e.g., low-income population, 
unknown HR status), and different outcome measures. Overall, existing evidence 
seems to support the survival outcome benefits of adherence to AET among women 
with HR-positive breast cancer. But there are still limited data on underserved 
populations. Further research with a large sample size and a rigorous study design is 
warranted. 
 
2.6.3 AET adherence and persistence  
Patient adherence and persistence are critical in maximizing AET treatment benefits. 
Current literature showed a broad range of adherence and early discontinuation rates 
ranging from 41% to 95.7% and 12% to 73%, respectively.22,23 Variations in adherence 
and persistence in these studies may be attributable to heterogeneity in methodology 
and study population. There is no gold standard method for measuring adherence and 
persistence of AET in clinical practice, nor is there a good biomarker available to 
measure the use of tamoxifen or AI.124 Therefore, almost all relevant studies used 
indirect methods to measure adherence and persistence, namely pharmacy 
claims/medical records data, or physician report/patient self-report data. In general, 
studies that used physician report or patient self-report data showed better results, with 
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adherence rates ranging from 77% to 94.7% 125–127 and non-persistence rates ranging 
from 21% to 31%.118,125,128,129 Due to their study design, these results may suffer from 
recall bias or social desirability bias, but they may facilitate the examination of 
modifiable factors associated with adherence and persistence. Most studies of AET 
adherence and persistence utilized pharmacy claims data, which had the advantage of 
large sample sizes, long follow-up time, and objective results. But pharmacy claims data 
may not capture actual medication-taking behaviors. It is also difficult to use this type of 
data to investigate modifiable predictors.  
Additionally, although adherence was defined as MPR ≥ 80% in these studies, non-
persistence/discontinuation was not defined consistently but was often operationalized 
in retrospective claims data studies as the discontinuation of drugs after exceeding a 
permissible gap.130 In AET persistence research, the definition of prescription fill gap 
ranged from 45 to 180 days, based on the pharmacological characteristics of the drugs; 
legitimate delays in refills, such as hospitalization; and the length of follow-up 
period.122,123,125,131–133 The discrepancies in definition may also result in variations in 
discontinuation rates. Furthermore, the length of follow-up period is crucial to adherence 
and persistence results since the literature has consistently shown an inverse 
relationship between AET adherence and use time.23,28,117,120,134–138 Many 
characteristics of study population such as age, race/ethnicity, SES, geographic 
residence, healthcare plan, and healthcare system factors may also influence patient 
adherence and persistence23; therefore, the inherent heterogeneity in study populations 
may cause differences in prevalence of AET adherence and persistence.  
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There is very limited research on AET use behaviors among breast cancer survivors in 
underserved regions such as Appalachia. And current research on the reasons for 
breast cancer disparities in Appalachia mainly focuses on breast cancer prevention, 
screening, and primary treatment and does not include adjuvant treatment use 
disparities. To facilitate comparison with the present study, we consulted previous 
pharmacy claims data studies in the U.S. and attempted to identify average AET 
adherence and persistence rates during the first two years. AET adherence rates were 
in the range of 70%-80%,116,117,138,139 and the discontinuation rates were fairly consistent 
at around 20% .27,28,117,123 Medicaid enrollees in North Carolina, one of the Appalachian 
states, had a below-average adherence to AET, at approximately 60%,27 while patients 
using mail-order pharmacy services seemed to be more adherent to AET, with an 
adherence rate of about 90% .28 
Several up-to-date systemic reviews 22,23,140 summarized potential factors associated 
with AET adherence and persistence among women with breast cancer. Factors 
associated with poor adherence and persistence, consistently demonstrated in the 
literature, included extreme age, increasing out-of-pocket costs of AET, seeing a 
general practitioner vs. an oncologist during follow-up care, switching between drugs, 
and treatment-associated side effects. Though the past two decades have produced a 
substantial literature on factors that contribute to AET adherence and persistence, there 
is still little research on modifiable factors like psychological or behavioral constructs 
that could guide the development of clinical interventions to improve AET use behaviors. 
In addition, there is a paucity of literature that systemically evaluates the relationship 
between access to cancer care and AET use. The addition of this literature could also 
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lead to policy intervention strategies that address the pathways linking social and 
behavioral factors to health disparities in underserved regions like Appalachia. 
 
2.7 Conceptual model 
To guide this study, we propose a conceptual model (Figure 2.3) that adapts the 
constructs from Donabedian’s structure-process-outcome framework141 and Andersen’s 
behavioral model for health service use142,143 and an extension of the Andersen’s model 
proposed by Pam Short and Roger Anderson (unpublished work), links them to 
Hendren and colleagues’ cancer health disparity model,144 and integrates the findings of 
published empirical work regarding AET use. Donabedian’s structure-process-outcome 
framework has been well developed as a comprehensive measurement of quality of 
medical care. Structure refers to the context and setting in which the health care is 
delivered,145 process describes the interaction between patients and healthcare 
providers throughout health care delivery, and outcome includes economic, clinical, and 
humanistic outcomes. On the other hand, Andersen’s behavioral model identifies the 
factors that affect access to and availability of healthcare and lead to the use of health 
services.142,143 It has been extensively applied in empirical research, especially in 
secondary data analysis studies of health utilization.146  
In cancer care, in particular, structural and process factors also reflect patient access to 
and quality of cancer care and could eventually influence cancer outcomes.84,144,147 
Structural factors may include structural barriers that patients experience in access to 
care and care coordination such as health insurance, financial burden, logistical barriers 
(e.g., geographic distance to the healthcare facility, transportation), follow-up care 
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referral, support, and the accessibility and availability of specialized cancer care. 
Process factors may include provider’s decision-making and prescribing behaviors, 
patient’s decision-making and treatment use behaviors, and cancer care coordination. 
The process of care may be influenced by patient-level clinical, demographic, and 
psycho-behavioral characteristics (e.g., cancer clinical status, marital status, 
race/ethnicity, SES, comorbidities), provider-level characteristics (e.g., competing 
demands, knowledge, practice experience, cultural competency), and the interaction 
between patient and provider (e.g., shared decision making, patient self-efficacy in 
provider-patient interaction, trust in healthcare system/provider). All these structural and 
process factors may in turn impact care outcomes, for instance, cancer survival, health-
related quality of life (HRQoL), and patient satisfaction.144 
The measures of access to care, as per the Andersen’s model and the extension 
proposed by Pam Short and Roger Anderson, include potential access, defined as the 
presence of characteristics or resources that enable individuals to seek medical care or 
services, when needed, and realized access, which is the actual utilization of medical 
care or services.142,143 According to the theory, which is supported by empirical 
evidence, potential access is assessed at the system- and individual- levels. System-
level characteristics here refer to SES, educational attainment, transportation barriers, 
community health risks, and healthcare provider resources at the county or area levels. 
Research has proven repeatedly that these geographic factors contribute substantially 
to breast cancer disparities in Appalachia including those related to screening and late-
stage diagnosis,5 as well as the receipt of guideline concordant primary10 and adjuvant 
treatments.63 Individual-level potential access includes three main components: 
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predisposing factors that are pre-existing characteristics of patients to predict the 
probabilities of using medical services or products,  enabling factors that refer to the 
ways available to patients to use the services or products, and need factors that 
generally indicate the severity of the disease and overall health status.143 To depict 
access to and quality of breast cancer care in Appalachia, predisposing factors in the 
model include patient demographics like age, race/ethnicity, marital status, and 
educational level; enabling factors include household income level, health care 
insurance and drug insurance, travel time to receive care, health literacy, 
health/medication knowledge and beliefs, social support, and patient activation144; need 
factors include breast cancer-related clinical status and comorbidities.  
Realized access, as a result of potential access, is operationalized by assessing the 
characteristics of the healthcare providers or facilities from which patients seek 
care.142,143 The receipt of optimal cancer care depends, in part, on the choice of cancer 
providers or oncology resources, which is primarily influenced by the following features: 
1) supply: the availability of standard and/or cutting-edge cancer care or treatment 
options; 2) demand: case volume; type and volume of cancer care procedures; 3) 
comprehensiveness or coordination: the type and range of services provided, or 
coordination of care if certain services like adjuvant chemotherapy are not provided at 
the facility; 4) proximity: geographic distance between patient and facility/provider, or 
transportation barriers. The specialization and accreditation status may partly reflect the 
supply and comprehensiveness features of the facility. Meanwhile, a phenomenon 
called “selective referral” may intertwine the features of demand and proximity. 
Selective referral indicates the possibility that patients who travel longer distances to 
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high-volume hospitals and designated cancer centers do so because oversight 
agencies and insurance providers attempt to move complicated cancer care to high-
volume hospitals and designated cancer centers.102 These patients may differ along 
unmeasured dimensions, such as clinical status, personality and sophistication, and 
patient-provider communication, which may also affect the providers’ guideline 
concordance and the patient’s adherence to provider recommendations. Furthermore, 
physicians’ decisions about when and how to treat breast cancer is not only based on 
their patients’ characteristics but also their own characteristics, including age, sex, years 
of practice, medical school, residency hospital, knowledge and specialty, and interaction 
with patients.144,148,149  
Patients’ medication adherence may also be affected by the factors discussed earlier, 
including access to care, care coordination, provider decision-making and behaviors, 
and medication-specific factors. Extremes of age, high out-of pocket costs, survivorship 
care by a general practitioner rather than an oncologist, drug-switching, treatment side 
effects or fear of side effects, lack of medication knowledge, insufficient social support, 
and low self-efficacy in provider-patient interactions are negatively associated with AET 
adherence and/or persistence.23,133,140,150 Additionally, individual clinical status, 
treatment choice, and medication use behaviors may influence treatment outcomes at 
clinical (e.g., breast cancer recurrence and survival), humanistic (e.g., health-related 
quality of life, patient satisfaction), and economic (e.g., health utilization and costs) 
levels.    
The current lack of strong evidence regarding the relative importance of the 
multidimensional factors associated with access to and quality of care limits our 
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knowledge and ability to develop targeted interventions to reduce cancer disparities in 
Appalachia. We develop a model that assesses multidimensional determinants to 
predict AET access, adherence and persistence by including systemic-level, individual-
level, facility-level, provider-level, and medication-related factors. According to the 
model, this study tested the hypothesis that patients who had better access to care 
were more likely to receive guideline-appropriate AET. Better access factors included in 
the study were better counties’ SES, higher county-level educational attainment, fewer 
transportation barriers and community health risks, higher household income, better 
medical and drug insurance benefits, poorer clinical prognosis, more comorbidities or 
more severe comorbidities, receiving BCS (vs. mastectomy), more breast-cancer-
related follow-up visits, receiving timely breast cancer primary treatment, as well as 
being treated in CoC-accredited, large facilities and by oncologists (vs. generalists). In 
addition, we examined whether patients who experienced less pill burden, fewer or 
more tolerable AET-associated side effects, fewer out-of-pocket drug costs, as well as 
better access factors, had a higher likelihood of AET adherence and persistence. Lastly, 
after controlling access factors, we investigated if those who were adherent to and 
persistent with their adjuvant treatments had a lower risk of death during the study 
period. Overall, this integrated conceptual framework can help us systemically evaluate 
these factors and link them to providers’ treatment guideline concordance and the 
patients’ AET medication use behaviors, which together affect the therapeutic outcomes 
of breast cancer patients in Appalachia.  
 43 
 
Figure 2.3 Conceptual model 
 
* indicates the variables measured in this study 
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CHAPTER 3 
METHODOLOGY 
This study assessed the relationships between access to cancer care resources, AET 
use, and survival among female breast cancer survivors in Appalachia. This section 
details the study population, design, and measurement, as well as the specific means 
by which the two study aims were achieved. 
 
3.1 Study design 
This was a retrospective cohort study from January 1, 2006 to December 31, 2008 of 
female breast cancer survivors who resided in the Appalachian counties of four states 
(PA, OH, KY, and NC) as defined by the ARC. We utilized claims data for Medicare, the 
primary health insurance for Americans aged ≥65 years. Medicare claims data have 
been extensively utilized in breast cancer care research for two main reasons.5,63,151,152 
First, older age is a significant risk factor for breast cancer. Second, Medicare claims 
data tend to be comprehensive and cover the full continuum of health care for enrollees 
who are not enrolled in a HMO.5 Furthermore, the Medicare Part D claims dataset is a 
good source for investigating AET use because AET is covered under Part D and Part 
D was initiated at around the same time as our study period.  
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The overall study design illustrated in Figure 3.1 comprised three main periods: the 
baseline period (one year before the first breast cancer diagnosis), the diagnosis-to-
AET period (the interval between the first diagnosis and the initiation of AET), and the 
follow-up period (from the date of the first AET prescription filled until death or the end 
of the observation, 12/31/2008). The primary outcomes were the receipt of guideline-
recommended AET, AET adherence and persistence, and overall survival. The study 
was approved by the University of Michigan’s Institutional Review Board (IRB), and data 
use was approved by CMS and each state’s cancer registry. 
 
Figure 3.1 Overall study design 
 
 
 
3.1.1 Data sources and linkage 
To achieve the study aims, we integrated data from multiple sources: we obtained 
individual characteristics from cancer registries and CMS Medicare claims data; system-
level characteristics from the ARC data reports, the 2010 U.S. census, the Area 
Resource File, the National Center for Health Statistics (NCHS), Centers for Disease 
Control and Prevention (CDC), and the National Cancer Institute (NCI); and 
provider/facility characteristics mainly from Medicare Provider of Service files and 
Medicare Physician Identification and Eligibility Records files. First, we linked women 
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who were diagnosed with breast cancer during 2006-2008 and tracked in the four states’ 
cancer registries to Medicare claims data using patient identifiers including name, social 
security number, gender, and birthdate. Then, we established the cross-link between 
patient data and system-level characteristics using county codes. We utilized Unique 
Physician Identification Numbers (UPIN) and National Provider Identifiers (NPI) to link 
patient claims to provider/facility factors. Completely de-identified data were used for 
final analyses. 
 
3.1.2 Study population 
For Aim 1, we followed these steps to obtain the study sample: 
1) Start with the 17,074 adult women who were diagnosed with primary breast 
cancer in the four states’ cancer registries. 
 
 
 
 
 
 
 
2) Confirm the breast cancer diagnosis and clinical stage in more detail (using data 
from cancer registries). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adult women with breast cancer who lived in the Appalachian counties 
of four states (PA, OH, KY, and NC) 
 
N= 17,074 
 
 
 Include: 1) cases in which the first diagnosis of primary breast cancer 
with a positive histology, cytology, or microscopic confirmation was in 
2007 and for which there were not multiple/concurrent non-breast 
cancer solid tumors within 90 days; 2) cases of cancer stage I-III; and 
2) cases with an estrogen receptor- or progesterone receptor-positive 
tumor 
 Exclude: 1) cases in the cancer registries coded as autopsy- or death 
certificate-only cases; and 2) breast cancer cases coded as M8540-
M8543 (Paget’s disease for breast cancer), M9050-M9055 
(mesotheliomas), M9140 (Kaposi sarcoma), M9590–M9989 
(lymphohematopoietic malignancies), or M8520 (lobular). 
N= 2,346 
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3)  Check the CMS Medicare enrollment (using data from Medicare claims). 
 
 
 
 
 
 
 
 
 
 
 
 
4)  Check the eligibility and definition of AET new users. 
 
 
 
 
 
 
 
 
 
 
 
 
 
5) Validate data quality by comparing the data from cancer registries and Medicare 
claims.  
 
 
 
 
 
 
 
 
Then, we followed additional steps to identify the final sample for Aim 2: 
1) From the final sample in Aim 1, choose a subset of subjects who were prescribed 
AET within one year following the diagnosis.  
Include: patients who were continuously enrolled in Medicare 
Parts A and B from 2006 to 2008 or until death, and 
continuously enrolled in Medicare Part D from the first breast 
cancer diagnosis to the end of the observation (12/31/2008) or 
until death. 
Exclude: patients who were enrolled in a Health Maintenance 
Organization or Medicare Advantage Program. 
N= 1,022 
 
Include: patients who had primary treatment for breast cancer 
(mastectomy or breast conserving surgery) within 180 days 
after the diagnosis.  
Exclude: 1) patients who had any AET prescription filled 
before receiving the primary treatment; and 2) patients who 
were not recommended to receive AET because of 
contraindications or who died prior to planned or recommended 
AET. 
N= 963 
 
Exclude: cases that had mismatching information across 
data sources (e.g., gender, date of birth, geographic 
residence) 
N=946    (Aim 1 final sample) 
 
 
. 
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2) Set follow-up days. (Note: the follow-up period was from the initiation of AET to 
12/31/2008 or death.) 
 
 
 
 
 
3.2 Variable measures 
3.2.1 Measurement of access to care 
3.2.1.1 Potential access 
   3.2.1.1 .1 System-level characteristics (at the county level) 
Socioeconomic status of counties: The Appalachian Regional Commission’s county 
economic status classification (2013) is an index-based, area-level economic status 
classification system that describes and tracks the economic situation of Appalachian 
counties.153 The index calculation is based on the average unemployment rate (2008-
2010), the per capita market income (2009), and the average poverty rate (2006-2010) 
of each Appalachian county. The original index has five categories. Each represents a 
percentile group based on the national index values of all US counties: distressed 
(worst 10%), at risk (worst 10-25%), translational, competitive (best 10-25%), and 
attainment (best 10%). It is a validated, specific measure of the economic status of 
Appalachian counties and has shown to be related to late stage diagnosis of breast 
cancer among Appalachian women.5 Its weakness may be the lack of a social 
component such as the family structure, wealth and home ownership, which may limit 
Include: patients who newly initiated AET within one year 
after diagnosis  
N=450 
 
Include: patients with at least 6 months of follow-up data 
N=428 (Aim 2 final sample) 
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its sensitivity to some potential area-based SES features that could lead to health 
disparities. In this particular study, this index was restructured  into three classifications: 
economically distressed, at risk, and others.5  
Educational attainment: ARC data reports were used to extract the county-level 
percentage of residents aged 25 and above with less than a high school diploma 
and the percentage with at least a bachelor's degree (2007-2011).153  
Transportation barriers:  We used the dummy variable of metropolitan and non-
metropolitan defined by the 2013 NCHS Urban–Rural Classification Scheme for 
Counties to evaluate the geographic varying effects of these Appalachian counties.154  
Community health risks: As per the Andersen’s model,142,143 infant mortality rates may 
reflect socioeconomic conditions, as well as the quality and effectiveness of a 
healthcare system,12 and can be used to evaluate community health risks at the local 
level. In addition, cancer mortality rates may also reflect the availability of and access to 
quality cancer care in the community. We extracted the 2007 infant mortality rates 
(reported as deaths per 1,000 births) at the county level from the linked birth/infant 
death records (2007-2010) produced by the CDC and NCHS.155 The 2007-2011 
average county-level cancer mortality rates were identified from the United States 
Cancer Statistics data provided by the CDC and NCI, and were presented as the 
annual age-adjusted, cancer-related death rates per 100,000 residents.156 
Healthcare provider resources: We identified the Health Professional Shortage Area 
(HPSA) designation, as defined by the U.S. Department of Health and Human Services, 
using data from the 2007–2009 Area Resources Files at the county level. Each 
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Appalachian county was categorized as being partially within a HPSA, entirely within a 
HPSA, or not within a HPSA.5 
 
3.2.1.1 .2 Individual-level characteristics 
 Predisposing factors 
Demographic information: The following demographic information were extracted from 
the cancer registries: 1) Age at diagnosis (in year 2007): 18–64, 65–74, 75-84, ≥85 
years old; 2) Race: white or non-white; 3) Marital status: married or not married; 4) 
Geographic residence: state of residence at diagnosis (PA, OH, KY, or NC). 
 Enabling factors 
Income: The 2007-2011 average estimates of annual median household income 
were extracted from the American Community Survey data using census block group 
codes.157 We created a categorical variable of the four quartiles of median household 
income. 
Health insurance benefits: 1) As discussed in Chapter 2, Medicaid and Medicare dual-
eligible enrollees may have additional insurance benefits; therefore, we created a dual 
Medicaid and Medicare eligibility indicator (yes/no) to evaluate the effect of different 
health plans on patient access to AET and AET use. Patients ever at the dual-eligible 
status during the study time were considered “yes”; 2) the average monthly out-of-
pocket drug costs: all payments paid by each patient for each drug claim in Medicare 
Part D were summed up, divided by follow-up days and then times 30 days; 3) whether 
patients reached the out-of-pocket threshold and began to receive catastrophic 
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coverage: Patients ever reaching the out-of-pocket threshold during follow-up were 
categorized as “yes”.  
Travel time to receive care: The largely rural environment, geographic isolation, and 
substantial transportation barriers in the Appalachian region may result in poor access 
to care, which further contributes to cancer disparities. Travel time to mammography 
centers is one of the currently available validated measures of spatial access to care, 
which has been shown to relate to late-stage diagnoses of breast cancer.158 Travel time 
is a direct, straightforward, and commonly-used measure of special access. It also has 
the strength of capturing distance decay, which is defined as the decrease of similarity 
as distance increases.159,160 In other words, travel time can tell the distinctions between 
the mammography center close to the patient and the one at the opposite boundary 
edge to the patient. But it cannot take in account the supply of healthcare resources and 
demand of patients.161 Nevertheless, our research group also compared different 
currently available validated spatial access measures and found that travel time to the 
closet mammography centers may be one of the best to predict the receipt of guideline-
recommended AET (unpublished work), therefore we included this measure in this 
present study. We calculated the estimated average travel time (in minutes) 
between the patient and the three closest mammography centers. We geocoded 
the addresses of patients and mammography centers. Travel network distances were 
calculated from each patient to each mammography center. The shortest travel network 
path between the patient and mammography center was determined as the distance to 
the nearest mammography center.  
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Need factors 
Cancer-related clinical information: We obtained information on breast cancer stage (I, 
II, III), tumor size (<1 cm, 1–2 cm, >2 cm, unknown), and lymph nodal status 
(negative or positive) from the cancer registries. 
Comorbidities: 1) The Charlson Comorbidity Index (CCI) was used to assess overall 
health status based on Medicare claims data during the baseline period. The CCI is a 
composite score used to predict mortality; a higher score represents more comorbidities 
or more severe comorbidities. We calculated the Deyo CCI, which contains 17 condition 
diagnoses based on the ICD-9-CM codes162, but we excluded the primary diagnosis of 
interest in this study—female breast cancer. Table 3.1 shows the detailed calculation 
and codes used; 2) we used the number of hospitalizations over the baseline 
period as a proxy for overall disease severity and burden. 
 
3.2.1.2 Realized access 
We designated the provider and affiliated facility with the most breast cancer-related 
Medicare claims after the diagnosis as the main provider and facility. We used NPI and 
UPIN to identify and link the provider and facility information. 
 
3.2.1.2.1 Facility characteristics 
Type, size and accreditation: 1) The American College of Surgeons ─ Commission 
on Cancer (CoC) provides accreditation for facilities to ensure high quality of cancer 
care. The CoC assigns each facility to a category based on its type, size, and case 
volume.163 The CoC categories included in our sample were community cancer program 
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(14.9%), comprehensive community cancer program (35.8%), NCI-designated 
comprehensive cancer program (3.0%), network cancer program (0.5%), academic 
comprehensive cancer program (11.5%), no designation (31.4%), and unknown (2.9%). 
We created a variable with the following categories: CoC-accredited, not accredited, 
and unknown; 2) the CMS 2007 Medicare Provider of Service file was used to 
determine number of beds (<100 beds, 100-200 beds, >200 beds, or unknown), 
facility type, and ownership (for-profit, government, not-for-profit, unknown).  
 
3.2.1.2.2 Provider characteristics 
Specialty and credential: We identified specialties and credentials using NPI and UPIN 
from Medicare claims data. Each healthcare provider was categorized as an oncologist, 
general practitioner, or other. 
Graduation year: The provider’s graduation year was used as a proxy for years of 
practice experience. It has shown to be associated with the receipt of guideline-
recommended AET among Appalachian women in previous literature.63 We categorized 
this variable into three groups: before 1980, the 1980s, and after 1989. 
 
3.2.2 Measurement of care coordination 
Number of breast-cancer-related follow-up visits: Most measurements of care 
coordination (88%) rely on survey instruments, and very few use administrative data.164 
Therefore, we attempted to create a measure that would capture the major components 
of care coordination among breast cancer survivors, including surveillance and 
prevention of recurrence, treatment-related long-term adverse effects, and overall 
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health.165 We calculated the number of breast-cancer-related follow-up visits after the 
primary treatment until death or until the end of our observation (detailed codes are 
presented in Table 3.2), according to the breast cancer follow-up care 
recommendations from the ASCO.55 
Timeliness of primary treatment initiation after the diagnosis: The timeliness with which 
a patient receives care may be affected by factors at the patient-, provider-, and 
healthcare system-levels166; timeliness may also be regarded as an indicator of quality 
of care and care coordination.144 We calculated the number of days between the 
diagnosis of breast cancer and the initiation of surgery. Since a gap of more than 60 
days is associated with worse survival outcomes,166 we dichotomized the variable to 
timely primary treatment and delayed primary treatment using 60 days as the cut-off 
point. 
  
3.2.3 Measurement of provider’s decision making and behaviors 
Two main measurements were chosen: 1) type of breast cancer treatment received: 
surgery type (breast-conserving surgery or mastectomy), radiation therapy (yes/no), 
and chemotherapy (yes/no); 2) if patients received AET, the type of AET used 
(tamoxifen, anastrozole, letrozole, and exemestane). We identified AET use using NDC 
codes and then classified patients into three groups: tamoxifen only, aromatase inhibitor 
(AI) only, and switching between tamoxifen and AI. Table 3.3 shows the specific 
procedure or drug codes used to identify breast cancer treatments. 
 
 
 55 
 
3.2.4 Measurement of medication-related factors  
The following medication-related factors were included: 1) the number of unique 
prescription drugs co-administered during the follow-up period, as a proxy measure 
of pill burden, was identified using NDC from the Medicare Part D claims data; 2) the 
season at the initiation of AET (spring, summer, fall, winter) was also included in 
analyses because the seasonal weather condition may have influences on travel and 
transportation, which in turn may affect patient behaviors of picking up their drugs. And 
the seasonal effects may be more phenomenal in a largely rural and mountainous 
environment such as Appalachia; 3) AET associated side effects. We utilized proxy 
measures for AET-associated side effects (e.g., osteoporosis, hot flashes/night sweats, 
arthralgia) using the indicators of the use of evidence-based pharmacological 
treatments (prescription drugs) for them. Dummy variables included whether or not 
patients used antidepressants (fluoxetine, paroxetine, venlafaxine, citalopram, 
gabapentin), bisphosphonates (zoledronic acid, alendronate, risedronate), and pain 
medications (opioids, gabapentin, pregabalin) during the follow-up period.  
 
3.3 Aim 1: Assess the relationship between access to cancer resources and the 
receipt of guideline-appropriate adjuvant endocrine therapy. 
 
3.3.1 Outcome measures 
3.3.1.1 The receipt of guideline-recommended AET  
To determine what constitutes guideline-recommended AET use, we referred to the 
NCCN and ASCO quality measures for breast cancer.167 Therefore, we defined the 
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receipt of guideline-appropriate AET as whether AET was prescribed to eligible female 
breast cancer survivors with positive hormone receptors within one year of diagnosis.  
 
3.3.2 Statistical analysis 
We conducted descriptive analyses of access-related factors, type of breast cancer 
treatment, and the receipt of guideline-recommended AET. We reported the means of 
continuous variables and frequencies and percentages of binary and categorical 
variables. We also presented the percentage of patients who received guideline-
appropriate AET, and of those patients, the respective percentages of patients who 
received tamoxifen, who received AI, and who switched between tamoxifen and AI.  
The logistic regression was utilized to assess the relationship between access to cancer 
care and the receipt of guideline-appropriate AET, and type of other breast cancer 
treatments were controlled. We utilized a robust standard error and tested the 
significance of the categorical variables in the model using the Wald test. The Hosmer-
Lemeshow goodness-of-fit test, multicollinearity, c-statistic, linear predicted value and 
linear predicted value squared (the “linktest” command in Stata) were checked. 
Likelihood ratio tests and Akaike's information criterion (AIC) and Bayesian information 
criterion (BIC) were used for model selection. 
 
3.3.3 Sensitivity analysis 
Furthermore, to account for the potential random effects of clustered county- and state- 
level factors, we re-estimated the model above using the multilevel mixed effect logistic 
regression.  
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3.4 Aim 2: Examine the associations between access to cancer care resources 
and adjuvant endocrine therapy (AET) adherence and persistence, as well as the 
effects of AET use outcomes on survival. 
 
3.4.1 Outcome Measures 
3.4.1.1 Adherence 
We calculated AET adherence for each individual using the Medication Possession 
Ratio (MPR). The MPR is a commonly used medication adherence measure using 
administrative claims data that has been adopted in a great deal of AET adherence 
research.22,23 It is defined as the ratio of the amount of days for which the drug was 
dispensed divided by the number of days for which drug was needed,168,169 which was 
determined in this study using the following equation170,171:  
 
Medication possession ratio (MPR) = number of days’ supply / (number of follow-up 
days ─ number of inpatient days) 
 
Additionally, the MPR was truncated between 0 and 1.2, as well as dichotomized into 
adherence and non-adherence using the conventional cut-off point of 0.8 (0 ≤ MPR < 
0.8: non-adherence; 0.8 ≤ MPR ≤ 1.2: adherence). For those who switched between 
tamoxifen and AI, we precluded any double-counting of the days when the patient took 
both tamoxifen and AI. The non-adherence rate refers to the percentage of patients who 
were not adherent. 
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3.4.1.2 Persistence 
Medication persistence is defined as the act of complying with a provider’s 
recommendations to use medications for a prescribed length of time.130 It is also 
commonly operationalized in retrospective claims data studies as the discontinuation of 
drugs after exceeding a permissible gap.130 In AET persistence research, the 
prescription fill gap has been defined as ranging from 45 to 180 days, based on the 
pharmacological characteristics of the drugs; legitimate delays in refills, such as 
hospitalization; and the length of follow-up period.27,122,123,125,131–133 Taking all of the 
above into consideration, we decided to define AHT non-persistence as a minimum 60-
day medication fill gap. Patients who switched drugs within 60 days were still 
considered persistent. The non-persistence rate (also referred to as early 
discontinuation rate) refers to the percentage of patients who were not persistent. 
 
3.4.1.3 Survival  
Overall survival was defined as the period from AET initiation until death. The follow-up 
period ended on December 31, 2008.  
 
3.4.2 Statistical analysis 
We conducted descriptive analyses of the access variables, medication-related factors, 
type of breast cancer treatment, and follow-up days using means for continuous 
variables and frequencies and percentages for binary and categorical variables. We 
assessed MPRs, adherence rates, and discontinuation rates among the three AET 
groups. We used the 2×2 contingency table and phi coefficient to assess the correlation 
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between AET adherence and persistence. Preliminary bivariate association analyses 
were conducted to find potential predictors of adherence, persistence, and survival. We 
conducted two-tailed t-tests for continuous predictors of adherence and chi-square tests 
for binary and categorical predictors of adherence. We used Kaplan-Meier survival 
curves and log-rank tests to assess the associations between each binary/categorical 
variable and persistence or survival time, as well as univariate Cox regression analyses 
to evaluate the relationships between each continuous variable and persistence or 
survival time. In particular, we utilized Kaplan-Meier survival curves and log-rank tests 
to assess the bivariate associations between AET adherence/persistence and overall 
survival. 
 
3.4.2.1 Adherence 
We conducted multivariate logistic regression to assess the relationship between 
access to cancer care and AET adherence. Other potential covariates included 
medication-related factors, type of breast cancer treatment, and follow-up days. We 
incorporated potentially significant predictors with a p value less than 0.25 in the 
bivariate association analyses into the final multivariate logistic regression model with a 
robust standard error. For the final logistic model of adherence, we also tested the 
significance of the categorical variables and checked the goodness-of-fit, 
multicollinearity, c-statistic, linear predicted value and linear predicted value 
squared (the “linktest” command in Stata). We also tested the potential random effects 
of clustered county- and state-level factors. 
 
 60 
 
3.4.2.2 Persistence 
We obtained multivariate-adjusted estimates of persistence time using the Cox 
proportional hazards (PH) model. We included in the final model only those predictors 
for which p < 0.25 in the bivariate association analyses. We checked the proportional 
hazard assumption of the variables in the final model. If a variable did not meet the 
assumption, we estimated a stratified model based on the variable.121  
 
3.4.2.3 All-cause mortality 
We conducted survival analyses to test the working hypothesis that, among breast 
cancer patients who received guideline-recommended adjuvant treatment, those who 
were adherent to and persistent with their adjuvant treatments had a lower risk of death. 
We plotted the Kaplan-Meier curves for overall survival to compare patients who were 
adherent to/persistent with AET with those who were not, and we used the log-rank test 
to compare these Kaplan-Meier curves. To allow for the multivariate comparison of 
these survival measures, we utilized the Cox PH regression model. In the models, we 
also adjusted the potential predictors with a p-value less than 2.5 in the bivariate 
association analyses. We checked the proportional hazard assumptions and goodness-
of-fit.  
 
3.4.3 Sensitivity analysis 
Sensitivity analyses were conducted to reduce the potential errors or uncertainty caused 
by the definitions of adherence and persistence, as well as to achieve a better 
understanding of the relationships. AET adherence and persistence were redefined 
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using MPR cutoff points ranging from 0.6 to 0.9 and a 90-day medication fill gap, 
respectively.  
For both study aims, the statistical significance level was set to p < 0.05. We utilized R 
3.0.2 for general data management, ArcGIS 10.1 for geo-related data management, and 
Stata 13 for analyses.   
 62 
 
Table 3.1 The ICD-9 codes and scores used in the calculation of the Charlson 
Comorbidity Index 
 
Condition Score ICD-9 code 
Myocardial 
Infarction 
1 '410','412' 
Congestive 
Heart Failure 
1 
'39891','40201','40211','40291','40401','40403','40411','40413','40491','40493', 
'4254','4255','4257','4258','4259','428' 
Peripheral 
Vascular 
Disease 
1 
'0930','4373','440','441','4431','4432','4438','4439','4471','5571','5579','V434' 
 
Cerebrovascular 
Disease 
1 '36234','430','431','432','433','434','435','436','437','438' 
Dementia 1 '290','2941','3312' 
Chronic 
Pulmonary 
Disease 
1 
'4168','4169','490','491','492','493','494','495','496','500','501','502','503', 
'504','505','5064','5081','5088' 
Connective 
Tissue Disease 
1 '4465','7100','7101','7102','7103','7104','7140','7141','7142','7148','725' 
Ulcer Disease 1 '531','532','533','534' 
Mild Liver 
Disease 
1 
'07022','07023','07032','07033','07044','07054','0706','0709','570','571','5733','
5734','5738','5739','V427' 
Diabetes without 
complications 
1 '2500','2501','2502','2503','2508','2509' 
Hemiplegia or 
Paraplegia 2 
'3341','342','343','3440','3441','3442','3443','3444','3445','3446','3449' 
Moderate to 
Severe Renal 
Disease 
2 
'40301','40311','40391','40402','40403','40412','40413','40492','40493','582', 
'5830','5831','5832','5834','5836','5837','585','586','5880','V420','V451','V56' 
Diabetes with 
End Organ 
Damage 
2 '2504','2505','2506','2507' 
Any Tumor 2 
'140','141','142','143','144','145','146','147','148','149','150','151','152','153',                  
'154','155','156','157','158','159','160','161','162','163','164','165','170','171','17
2','175','176','179','180','181','182','183','184','185','186','187','188',                   
'189','190','191','192','193','194','195','200','201','202','203','204','205','206','20
7','208','2386’ 
Moderate to 
Severe Liver 
Disease 
3 '4560','4561','4562','5722','5723','5724','5728' 
Metastatic Solid 
Tumor 
6 '196','197','198','199' 
AIDS 6 '042','043','044' 
Note:  the disease of interest ─ female breast cancer diagnosis ─ was removed in “any tumor” 
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Table 3.2 Codes used for calculating the number of breast-cancer-related follow-up visits 
 
ICD-9-CM code 
(diagnosis) 
ICD-9-CM code 
(procedure) 
HCPCS/CPT code 
General medical 
examination 
174.0-174.9, 
V10.3 
V70.0-V70.2, 
V72.62 
99395, 99396, 99397, 99385, 99386, 
99387 
General counselling 
or preventive 
medicine counseling 
and/or risk factor 
reduction 
intervention(s) 
174.0-174.9, 
V10.3 
V65.3, V65.40, 
V65.41, 
V65.49 
99201, 99202, 99203, 99204, 99205, 
99212, 99213, 99214, 99215, 
99241,99242,99243,99244,99245, 
99341, 99342, 99343, 99344, 99345, 
99347, 99348, 99349, 
99350,99401,99402, 99403, 99404, 
99411, 99412 
 
Clinical breast cancer 
examination, 
mammography 
174.0-174.9, 
V10.3 
 V76.11, V76.19 
S0613, 77055, 77056, 77057, 
G0202,G0204, G0206,  77051(used 
with 77055 or 77056), 77052 (used 
with 77057 or G0202)  
Pelvic examination 
174.0-174.9, 
V10.3 
V72.31, V76.2 57410, G0101 
Genetic counseling 
174.0-174.9, 
V10.3 
V26.31, V26.32, 
V82.71, V82.79 
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Table 3.3 List of procedure and drug codes used to identify breast cancer treatments  
 ICD-9 CPT/HCPCS 
SSC
* 
Surgery 
Breast conserving 
surgery 
85.20-
85.23,85.
25 
19120,19125,19126,19160,19162,19301,19302 
10-
29 
Mastectomy 
85.33-
85.36,85.
41-85.48 
19220,19180,19182,19200,19240,19303,19304,19305,19306,19307,19
340,19342 
30-
80 
 
Radiation 
V58.0, 
V66.1, 
V67.1, 
92.20-
92.29 
77401-77418, G0174,G0178,G0179, 77520-77525, 77750-77790  
Chemotherapy 
V58.1x, 
V66.2, 
V67.2, 
99.25 
95990, 95991, 96400 - 17, 96420,96440,96450,96520,96530, 96545, 
96549, C9205, C9259, C9280,C9415, C9420, C9421,G0355,G0357, 
G0358,G0359, G0360, G0361,G0362,G0363, J0460, J0640, J1051, 
J2405, J8520,J8521,J8530,J8600, J8610,J8705,J8999, J9000, J9001, 
J9010,J9015,J9020, J9031,J9035,J9040,J9041,J9045, J9050, J9055, 
J9060,J9062,J9065,J9070, J9080,J9090,J9091,J9092, J9093, J9094, 
J9095,J9096,J9097, J9100,J9110,J9120,J9130,J9140, J9150, J9160, 
J9165,J9170,J9178, J9180,J9181,J9182,J9185,J9190, J9200, J9201, 
J9206,J9208,J9209,J9211,J9212,J9213,J9214,J9216, J9225, J9230, 
J9245,J9250,J9260, J9263,J9264,J9265,J9266,J9268, J9270, J9280, 
J9290,J9291,J9293, J9305,J9310,J9320,J9340,J9350, J9360, J9370, 
J9375,J9380,J9390, J9999, K0415,K0416, Q0083, Q0084, Q0085, 
Q2043,S0177,S0178,S0181, X7052, X7624, X7632, X7642, X7647, 
X7648 
 
NDC for endocrine therapy** 
Tamoxifen 
605053035, 605053036, 636294413, 550452703, 637390269, 003780144, 003780274, 
548683004, 548684287, 000930782, 000930784, 005912232, 005912233, 005912472, 
005912473, 000544831, 000544834, 000548831, 000548834, 001725656, 001725657, 
003100600, 003100604, 003100730, 003100731, 005550446, 005550904, 387790341, 
515520838, 519272976, 545693765, 545695716, 545695857, 629911151, 633040600, 
633040601, 661050832, 001791952, 003100446, 005550446, 005550904, 548683004, 
548684287, 558870872, 662670873, 004800782, 530021032, 551600149, 551600150, 
004800784, 260530044, 485816221, 485816222, 620370964, 625405656, 625405657, 
511292622, 511294218, 511294662, 595640144, 001791299, 125810600, 511291952, 
625840600, 637390269 
Aromatase 
inhibitors (AIs) 
000097663, 000780249, 003100201, 122800346, 499990986, 545695714, 545695731, 
548684151, 548685000, 548685261, 477810108, 000540080, 000095206, 597622858, 
108297663, 001791657, 170881004, 422910373, 633230772, 000540269, 000937620, 
003782071, 006034180, 167290034, 247240030, 519910759, 605053255, 683820363, 
004807620, 422540243, 548686252, 551110646, 578842021, 621750888, 627560511, 
658410744, 680840803, 001791889, 511291122, 353560270, 007815356, 422910105, 
430630383, 510790323, 631870080, 633230129, 000540164, 000937536, 001151261, 
003786034, 009046195, 009046229, 165710421, 167290035, 519910620, 636295269, 
658410743, 680840448, 260530006, 604290286, 420430180, 602580866, 605052985, 
636720015, 663360533, 664350415, 678770171, 680010155, 683820209, 001790068, 
216950990, 422540161, 548686130, 551110647, 621750710, 627560250 
*codes used in cancer registries 
** First 9-digit NDC  
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CHAPTER 4 
DISSERTATION MANUSCRIPT ONE 
ACCESS TO CANCER CARE AND ADJUVANT TREATMENT UTILIZATION AMONG 
BREAST CANCER SURVIVORS IN APPALACHIA 
 
Abstract 
Background: The Appalachia region of the U.S. experiences excess cancer mortality 
and a lack of access to cancer care resources. Current research on the reasons for 
breast cancer disparities in Appalachia mainly focuses on breast cancer prevention, 
screening, and primary treatment and does not include adjuvant treatment use 
disparities. This study aimed to investigate the utilization of adjuvant endocrine therapy 
(AET) among Appalachian female breast cancer survivors and to evaluate systemically 
the relationship between access to cancer care and AET use in this underserved region.  
Methods: This was a retrospective cohort study from January 1, 2006 to December 31, 
2008 of female breast cancer survivors who resided in the Appalachian counties of four 
states (PA, OH, KY, and NC). We analyzed a linked dataset from cancer registries, 
Medicare claims, and the U.S. census, as well as healthcare provider and facility 
information. We included Medicaid-enrolled adult women diagnosed with invasive, non-
metastatic, hormone-receptor-positive breast cancer. The multivariate logistic 
regression was used to assess the relationship between access to cancer care and the 
receipt of guideline-appropriate AET.  
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Results: Only 450 of the 946 eligible patients (47.6%) received guideline-recommended 
AET; for these patients, the most commonly prescribed AET was aromatase inhibitors 
(74.7%), followed by tamoxifen (18.9%). 6.4% switched between these two drug classes. 
Logistic regression results revealed that the receipt of guideline-concordant AET was 
associated with shorter travel time to receive care, dual Medicare and Medicaid 
eligibility, being unmarried (vs. married), and living in Pennsylvania (vs. Ohio). 
Conclusions: Geographic and socioeconomic factors such as travel time to receive 
care and healthcare plan type are important elements that could contribute to breast 
cancer treatment disparities in Appalachia. The findings may add to evidence for 
developing targeted intervention strategies to reduce cancer disparities in Appalachia. 
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Introduction 
The Appalachian region of the United States (U.S.) is characterized by a largely rural 
environment, high poverty rates, poor access to adequate cancer care, and 
demographical homogeneity. Forty-two percent of the region’s population is rural,2 83.9% 
is white,1 25.7% live in a high poverty area,3 and 16.5% have less than a high school 
education.1 All of these figures are higher than the respective national averages.  
The National Cancer Institute (NCI) classifies the Appalachian population as a special 
population of interest due to the significant cancer outcome disparities for most common 
cancers .4–6 Among Appalachian women, breast cancer is the most commonly 
diagnosed cancer and has the second highest mortality rate following lung and 
bronchus cancer.7 In general, breast cancer mortality in the thirteen Appalachian states 
was about 7% higher than in the other thirty-seven states (p < 0.05).106 Additionally, 
breast cancer mortality has declined in recent decades nationwide, but the breast 
cancer mortality decline in Appalachia has been only about half that of the non-
Appalachian regions.11 This significant disparity may be partly explained by the higher 
prevalence among Appalachian women of modifiable risk factors associated with breast 
cancer including inadequate fruit and vegetable consumption, lack of physical activity, 
and obesity,7,8 as well as by the lower rates of receipt of guideline-recommended 
prevention (e.g., mammogram in women over 408,9) and primary treatment (e.g., 
guideline-appropriate adjuvant radiation therapy after breast conserving surgery 
[BCS]10). So far, however, research into the reasons for breast cancer outcome 
disparities in Appalachia has mainly concentrated on breast cancer prevention and 
screening, as well as primary cancer treatment, and not on adjuvant treatment use. 
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Among the factors that are likely contributing to cancer disparities in Appalachia, lack of 
access to adequate effective cancer care is critical. Rural residence, geographic 
isolation, lack of public transportation, underdeveloped telecommunication infrastructure, 
high poverty and unemployment rates, inadequate medical resources, a shortage of 
healthcare professionals, lower levels of educational attainment, and attitudinal and 
cultural factors in Appalachia may all result in poor access to care.9,12–14  
Despite the substantial cancer disparities and the NCI’s particular interest in Appalachia, 
there have been relatively few studies of cancer issues in this region, primarily for lack 
of data and of a well-represented study sample. Kimmick et al (2014),63 a recently 
published article with a particular focus on Appalachian breast cancer patients, linked 
Medicare claims data with four Appalachian states’ cancer registries to examine the 
treatment guideline concordance among women diagnosed with stage I-III breast 
cancer. The present study utilized the same dataset to further investigate the utilization 
of adjuvant endocrine therapy (AET) among female breast cancer survivors in this 
underserved region. In particular, the relationship between access to cancer care and 
AET use was evaluated systemically based on an integrated conceptual model.  
 
Methods 
1. Study design and data source  
This was a retrospective cohort study from January 1, 2006 to December 31, 2008 of 
female breast cancer survivors who resided in the Appalachian counties of four states 
(PA, OH, KY, and NC), as defined by the Appalachian Region Commission (ARC). 
 69 
 
Eligible patients had a primary breast cancer diagnosis with a positive histology, 
cytology, or microscopic confirmation in 2007. The study design comprised a baseline 
period that began one year before the diagnosis date, and patients were followed up 
with from the diagnosis date until death or until the end of the observation (12/31/2008). 
Two main datasets, Medicare claims data and cancer registries, were linked using 
patient identifiers including name, social security number, gender, and birthdate, a 
method validated in previous studies.5,63 System-level characteristics were acquired 
using county names or codes from ARC data reports, the 2010 U.S. census, the Area 
Resource File, the National Center for Health Statistics (NCHS), the Centers for 
Disease Control and Prevention (CDC), and the NCI. Provider/facility characteristics 
were mainly identified using the Unique Physician Identification Numbers (UPIN) and 
National Provider Identifiers (NPI) from the Medicare Provider of Service files and the 
Medicare Physician Identification and Eligibility Records files.  
Completely de-identified data were used for final analyses. The study was approved by 
the University of Michigan’s Institutional Review Board (IRB), and data use was 
approved by the Centers for Medicare and Medicaid services (CMS) and each state’s 
cancer registry.  
 
2. Study population  
The study sample was obtained based on a series of inclusion and exclusion criteria 
specified in Figure 4.1. Among the 17,074 adult women in the Appalachian counties 
who were diagnosed with primary breast cancer in the four states’ cancer registries, we 
included those who were diagnosed with confirmed stage I-III, hormonal receptor (HR) 
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positive, primary breast cancer in 2007. Eligible patients were continuously enrolled in 
Medicare Parts A and B during the study time and in Part D from the time of the first 
breast cancer diagnosis. We excluded those who were enrolled in a Health 
Maintenance Organization (HMO) or Medicare Advantage Program due to the lack of 
claims data. Our study subjects were those who survived the primary breast cancer 
treatment (surgery) and were eligible for AET, but did not have AET before. Lastly, we 
verified the data and excluded cases with mismatching information across data sources.  
 
3. Outcome measures 
The National Comprehensive Cancer Network (NCCN) and the American Society of 
Clinical Oncology’s (ASCO)’s recommendations and method167 were used to determine 
what constitutes guideline-recommended AET use. Therefore, we defined the receipt of 
guideline-appropriate AET as whether AET was prescribed to eligible female breast 
cancer survivors with positive-HR status within one year of biopsy-confirmed diagnosis.  
 
4. Covariate measures 
We adapted the constructs from Andersen’s behavioral model for health service 
use142,143 as the theoretical background and integrated the findings of empirical work 
regarding AET medication use to guide this study. As per Andersen’s model, the 
presence of characteristics or resources that enable patients to seek medical care can 
be classified into three categories: predisposing factors that are pre-existing 
characteristics of patients to predict the probabilities of using medical services or 
products, enabling factors that refer to the ways available to patients to use the services 
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or products, and need factors that generally indicate the severity of the disease and 
overall health status.143 These can be assessed at both the system level and the 
individual patient level. These characteristics may impact patients’ actual utilization of 
medical care. Realized access is often operationalized by assessing the features of 
healthcare providers or facilities and quality of care, such as care coordination. Taken 
together, these individual and provider characteristics may influence providers’ decision-
making and prescribing behaviors, and it is the combination of all of these factors that 
affects patient medication use pattern, which, subsequently, may also influence cancer 
health outcomes.   
 
4.1 Measurement of access to care 
4.1.1 Potential access  
System level characteristics (at the county level): 1) The counties’ socioeconomic 
status was measured using the Appalachian Regional Commission’s 2013 county 
economic status classification system,153 an index calculated based on the average 
unemployment rate (2008-2010), the per capita market income (2009), and the average 
poverty rate (2006-2010) of each Appalachian county. The index was utilized to sort 
counties into three groups: economically distressed, at risk, and others5; 2) The county-
level educational attainment was assessed using ARC data reports and recorded the 
percentage of residents aged 25 and over with less than a high school diploma and the 
percentage with at least a bachelor's degree (2007-2011)153; 3) The urban–rural 
geographic residence was determined using the 2013 NCHS Urban–Rural Classification 
Scheme for Counties. The counties were classified as either part of a metropolitan area 
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or not154; 4) Community health risks were operationalized as infant and cancer mortality 
rates. We extracted the 2007 infant mortality rates (deaths per 1,000 births) at the 
county level from the linked birth/infant death records (2007-2010) produced by the 
CDC and the NCHS.155 We identified the average annual age-adjusted, cancer-related 
death rates (deaths per 100,000 people, 2007-2011) from the United States Cancer 
Statistics data provided by the CDC and the NCI 156; 5) Health Professional Shortage 
Area (HPSA) designations were drawn from the 2007–2009 Area Resources File at the 
county level. Each Appalachian county was categorized as being partially within a 
HPSA, entirely within a HPSA, or not within a HPSA.5 
Individual level characteristics:  1) Predisposing factors: demographic information 
was extracted, such as age at diagnosis, race, marital status, and state of residence at 
diagnosis from the state cancer registries; 2) Enabling factors: the 2007-2011 average 
estimates of annual median household income were extracted from the American 
Community Survey data157 using census block group codes, and a categorical variable 
of the four quartiles of median household income was created. In addition, we created a 
dual Medicaid and Medicare eligibility indicator to evaluate the effect of different 
healthcare benefits on patient access to AET. The estimated average travel time (in 
minutes) from the patient to the three closest mammography centers was also 
calculated. Travel time to mammography centers is one of the currently available 
validated measures of spatial access to care, which has been shown to relate to late-
stage diagnoses of breast cancer.158 We geocoded the addresses of patients and 
mammography centers and calculated travel network distances from each patient to 
each mammography center. The shortest travel network path between the patient and 
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mammography center was determined as the distance to the nearest mammography 
center; 3) Need factors: we obtained cancer-related information including breast cancer 
stage (I, II, III), tumor size (<1 cm, 1–2 cm, >2 cm, unknown), and lymph nodal status 
(negative or positive) from the cancer registries. Patients’ comorbidities and overall 
health statuses were assessed using the number of hospitalizations over the baseline 
period and the Charlson Comorbidity Index (CCI). The CCI is a composite score used to 
predict mortality; a higher score represents more comorbidities or more severe 
comorbidities. Specifically, we utilized the Deyo CCI, which contains 17 condition 
diagnoses based on the ICD-9-CM codes,162 but we excluded the primary diagnosis of 
interest in this study—female breast cancer.  
 
 4.1.2 Realized access 
Facility characteristics: 1) The American College of Surgeons ─ Commission on 
Cancer (CoC) provides accreditation for facilities to ensure high quality of cancer 
care.163 We created a variable using the categories of CoC-accredited, not accredited, 
and unknown; and 2) We acquired information on number of beds (<100 beds, 100-200 
beds, >200 beds, or unknown), facility type, and ownership (for-profit, government, not-
for-profit, unknown) from the CMS 2007 Medicare Provider of Service files.  
Provider characteristics: 1) Specialty: Specialties were obtained using NPI and UPIN 
from Medicare claims data. Each healthcare provider was identified as an oncologist, a 
general practitioner, or others; 2) Graduation year: The provider’s graduation year was 
used as a proxy for years of practice experience and may be associated with patients’ 
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receipt of guideline recommended AET.63 We categorized this variable into three groups: 
before 1980, the 1980s, and after 1989. 
Care coordination: 1) We calculated the number of breast-cancer-related follow-up 
visits between primary treatment and death or the end of the observation period using 
the ASCO’s recommended follow-up care guidelines for patients with breast cancer55; 2) 
We measured timeliness of primary treatment initiation using the number of days 
between diagnosis and the initiation of surgery. Because a gap of more than 60 days is 
associated with worse survival outcomes,166 the variable was dichotomized to timely or 
delayed primary treatment using a cut-off point of 60 days. 
 
   4.1.3 Provider’s decision making and behaviors 
Two main measurements were chosen: 1) type of breast cancer treatment received: 
surgery type (BCS or mastectomy), radiation therapy (yes/no), and chemotherapy 
(yes/no); 2) if patients received guideline-recommended AET, we identified the type of 
AET used (tamoxifen and aromatase inhibitors [AIs] including anastrozole, letrozole, 
and exemestanes) using NDC codes.  
 
5. Statistical analyses 
We conducted descriptive analyses of access-related factors, type of breast cancer 
treatment, and the receipt of guideline-recommended AET. We reported the means of 
continuous variables, and the frequencies and percentages of binary and categorical 
variables. We also presented the percentage of patients who received guideline-
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appropriate AET, and of those patients, the respective percentages of patients who 
received tamoxifen, who received AI, and who switched between tamoxifen and AI. 
The logistic regression model was utilized to assess the relationship between access to 
cancer care and the receipt of guideline-appropriate AET, and type of other breast 
cancer treatments were controlled. We utilized a robust standard error and tested the 
significance of the categorical variables in the model using the Wald test. The Hosmer-
Lemeshow goodness-of-fit test, multicollinearity, c-statistic, linear predicted value and 
linear predicted value squared (the “linktest” command in Stata) were checked. We 
tested the interactions between the state of residence and county economic status, as 
well as the state of residence and HPSA designation. Likelihood ratio tests and Akaike's 
information criterion (AIC) and Bayesian information criterion (BIC) were used for model 
selection. Furthermore, to account for the potential random effects of clustered county- 
and state- level factors, the final model was re-estimated using the multilevel mixed 
effect logistic regression. The level of significance was set at p < 0.05 a priori. We 
utilized R 3.0.2 for general data management, ArcGIS 10.1 for geo-related data 
management, and Stata 13 for analyses.  
 
Results 
Our study included a total of 946 Medicare-enrolled adult women with invasive, non-
metastatic breast cancer who lived in the 148 Appalachian counties of four states (KY, 
NC, OH, and PA). Table 4.1 and Table 4.2 show the descriptive statistics for county-, 
individual-, and facility/provider-level characteristics. Nearly half of the counties (45.3%) 
were economically distressed or at risk, and all of the economically competitive counties 
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were in Pennsylvania. Most counties were designated as non-metropolitan areas 
(68.2%), and only 22 of the 148 counties (14.9%) were not classified as health 
professional shortage areas (HPSA). In addition, these counties are disadvantaged 
compared to the national averages in terms of the percentage of the population aged 25 
and over with less than a high school diploma (18.9% vs. 14.6%), the percentage of the 
population aged 25 and over with at least a bachelor's degree (15.7% vs. 28.2%), the 
infant mortality rate (7.2 vs. 6.8, measured as deaths per 1000 births), and the cancer 
mortality rate (197.5 vs. 175.1, measured as deaths per 100,000 residents). 
We followed the study population for a period of 18 months, on average. The study 
population had a mean age of 75 years old, and almost all of the women were white 
(97%), underscoring the racial homogeneity of this region. Approximately 41.6% of 
patients were married; 18.4% were eligible for both Medicare and Medicaid. The 
average travel time to the closest three mammography centers was 16 minutes. The 
majority of patients were diagnosed with stage I or II breast cancer (90%) and with 
negative lymph nodes (72.9%). About two-thirds of patients were treated in CoC-
accredited cancer programs (65.7%) and in large facilities with over 200 beds (64.6%). 
In addition, most patients sought breast-cancer-related follow-up care from general 
practitioners (60.6%); the mean number of breast-cancer-related follow-up visits was 
2.16. In terms of breast cancer treatment, most received BCS (63.2%) vs. a 
mastectomy (36.8%); 63% did not receive radiation; half received chemotherapy 
(50.4%). Only 450 patients of the 946 final study subjects (47.6%) received guideline-
recommended AET. Among those who received guideline-recommended AET, the most 
 77 
 
commonly prescribed AET was an AI (74.7%), followed by tamoxifen (18.9%); only 6.4% 
of patients switched between these two drug classes. 
Table 4.3 presents the results of multivariate logistic regression analysis of the receipt 
of guideline-recommended AET. We did not include race, facility ownership, or facility 
beds variables in the final model because of extreme small cell or multicollinearity 
issues. We found that geographic and enabling factors had important effects on access 
to guideline-concordant AET in Appalachia. Married women were less likely to receive 
guideline-recommended AET (OR = 0.63, p = 0.003). Breast cancer patients with dual 
Medicaid and Medicare eligibility had about four times greater odds of receiving 
guideline-recommended AET compared to those who with Medicare only (OR = 4.24, p 
< 0.001). Breast cancer patients with longer travel time to receive care were less likely 
to receive guideline-recommended AET (OR = 0.98, p = 0.02). Moreover, Ohio 
residents were less likely to receive guideline-recommended AET than Pennsylvania 
residents (OR = 0.60, p = 0.02). In addition, the interactions between the state of 
residence and county economic status as well as between the state of residence and 
HPSA designations were tested. But adding these interaction terms did not significantly 
improve our model based on the results of likelihood ratio tests, AIC and BIC, so we 
retained the model without interactions. In addition, the model was also re-estimated 
using multilevel mixed effect logistic regression with county- and state-level random 
effects. But the likelihood ratio tests showed no significant results, indicating no 
preference over regular logistic regression. Therefore, we chose the regular multivariate 
logistic regression as our final model. 
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Discussion  
The lack of strong evidence regarding the relative importance of the multidimensional 
factors associated with access to quality care and standard treatment may limit our 
knowledge and ability to develop targeted interventions to reduce cancer disparities in 
Appalachia. Therefore, this study investigated AET utilization and associated multilevel 
access factors among Appalachian breast cancer survivors. To systemically evaluate 
access-to-care issues in Appalachia, we constructed a linked database by integrating 
various data sources under the guidance of a conceptual framework. 
This study showed a low prevalence rate (47.6%) of guideline-recommended AET use 
among Appalachian breast cancer survivors compared to the average national rate 
(74%) for Medicare enrollees with Part D benefits according to the Surveillance, 
Epidemiology, and End Results (SEER) and Medicare data.116 The difference may be 
due to undertreatment in our population, or it may be attributable to our study design: 
we included only new users who used endocrine therapy for adjuvant treatment 
purposes, not as chemoprevention or neoadjuvant therapy or for metastatic cases. 
Another study of new AET users enrolled in a commercial health plan in Massachusetts 
also found relatively low guideline-recommended AET use (58%).117 Our results also 
showed more AI use than tamoxifen use in our population, which may have several 
explanations: 1) we had an older sample, so most women may have been 
postmenopausal at diagnosis. For these patients, AIs are the first-place adjuvant 
treatment as per clinical recommendations; 2) More and more evidence has emerged to 
support AI use since the start of the new century, and there seems to have been an 
increasing trend toward AI use around the late 2000s116; 3) Oncologists appear to prefer 
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prescribing AIs rather than tamoxifen to elderly women because of their efficacy and 
tolerability.172 In addition, if we had a longer follow-up time, we might have seen more 
switching between drug classes.  
The study findings corroborate the deficiencies in access to care in Appalachia. Our 
results suggested that the longer patients spent traveling to receive cancer care, the 
less likely they were to receive guideline-recommended adjuvant treatment. Previous 
research reached similar conclusions regarding the transportation barriers to receiving 
guideline-recommended breast cancer prevention care and primary treatment in 
Appalachia. Wheeler et al (2014), a study in North Carolina, found that urban/rural 
residence and travel distance to the radiation center could predict whether patients 
received radiation therapy.110 A patient self-reported study in West Virginia found that 
having health insurance and being able to access medical care without delays due to 
transportation problems were significantly associated with better adherence to 
mammography screening guidelines.107 Likewise, another qualitative study of 
Appalachian women’s perspectives on breast cancer screening produced similar 
findings.108  
Therefore, our findings further underscore the importance of reducing transportation 
barriers and improving geographic access to care among Appalachian breast cancer 
patients so as to reduce adjuvant treatment disparities. Moreover, nearly half of our 
study counties were economically distressed or at risk, and there were socioeconomic 
variations across states. Pennsylvania had the fewest economically distressed 
Appalachian counties and had no whole Appalachian county that was located in a 
HPSA, which may partly explain the higher likelihood of receiving guideline-
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recommended AET in Pennsylvania. Kimmick et al (2014) also found that female breast 
cancer patients living in Pennsylvania were more likely to receive guideline-
recommended endocrine therapy, chemotherapy, and radiation therapy than residents 
in North Carolina.63 The treatment disparities across states may correlate to multiple 
factors including geographic environment, healthcare system, and state health policy, 
the investigation of which warrants further research efforts.63 We did not find significant 
relationships between area-level SES or health professional shortage and receipt of 
guideline-recommended AET. 
In addition to geographic, area-specific predictors, the receipt of guideline-
recommended AET among Appalachian breast cancer survivors seem also to be 
related to individual SES factors such as type of healthcare plan benefits. We found that 
dually eligible beneficiaries were much more likely to receive guideline-recommended 
AET compared to their non-dual counterparts. Although dually eligible beneficiaries are 
generally more vulnerable in health, with more chronic and severe health conditions, 
and more economically distressed,114 they are entitled to several additional health 
benefits such as automatic enrollment in Part D drug plans and no monthly premium or 
deductibles. Many states’ Medicaid programs also help with copayments or out-of-
pocket costs for the drugs that are not included in the Medicare Part D formulary. In 
addition, during the transition to Part D, many states developed contingency plans to 
help dually eligible beneficiaries retain drug coverage through Medicaid before they 
could access Part D drug benefits.113 These differences in health benefits may mitigate 
patients’ financial burden and difficulties with access to medications and drug utilization.  
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Our findings should be considered in the context of several limitations. First, because of 
the nature of our study design, we could not establish causal inference but could only 
show associations. Second, our study’s duration and sample size limited our ability to 
determine differences in direct outcomes such as survival and breast cancer recurrence: 
survival differences resulting from AET use can usually be identified at 5-10 years 15,123; 
at least 27 outcome events in each treatment arm are required.173 Third, given the 
limited data availability and accessibility, our study lacked other detailed information 
such as individual-level educational attainment and household income, treatment facility 
location, prescriber information, accurate indications for the prescribed drugs, and data 
from the West Virginia residents. Although we attempted to use proxy measures to 
ascertain this information, it would be better if direct measures could be used. Lastly, 
the generalization of our results may be limited to initial oral AET use among elderly 
Appalachian women with invasive, non-metastatic, HR-positive breast cancer. We did 
not include those who used endocrine therapy as a primary treatment (no surgery) or 
who used ovarian suppression. Our population was also generally older than the typical 
breast cancer patient population; therefore, caution should be used when generalizing 
the results to other populations. 
 
Conclusion 
Despite these limitations, this study is among the first to examine the important question 
of how access to cancer care resources impacts AET utilization among Appalachian 
women with breast cancer. We found that geographic and socioeconomic factors such 
as travel time to receive care and type of healthcare plan contributed significantly to 
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breast cancer treatment disparities in Appalachia. The approach we established in this 
study may not only provide insights into cancer disparities in Appalachia but also have 
implications for investigating access-to-care disparities in other comparable 
underserved regions.  
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Figure 4.1 Flowchart of obtaining the final study sample 
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Table 4.1 Descriptive statistics of system-level characteristics (by county) (N = 
148) 
Variables Mean (SD) 
Percentage of less than high school graduate among persons aged 25 
and over (%) 
  18.9 (7.6) 
Percentage of at least a bachelor's degree among persons aged 25 
and over (%) 
  15.7 (6.3) 
Infant death rate per 1,000 births     7.2 (0.83) 
Annual age-adjusted, cancer-related death rate per 100,000 population 197.4 (28.1) 
 Frequency 
(%) 
ARC's county economic status  
            Distressed  36 (24.3%) 
            At risk 31 (21.0%) 
            Others 81 (54.7%) 
Urban-rural classification  
            Metropolitan       47 (31.8%) 
            Non-metropolitan 101 (68.2%) 
Health Professional Shortage Area (HPSA) designation   
            Whole county in HPSA 47 (31.7%) 
            Part county in HPSA 79 (53.4%) 
            Not in HPSA 22 (14.9%) 
SD = Standard Deviation, ARC = Appalachian Region Commission 
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Table 4.2 Descriptive statistics of individual, facility and provider characteristics 
of final study population (N = 946) 
Variables Mean (SD) 
Average travel time to the three closest mammography centers 
(minute) 
16.0 (10.0) 
Baseline Charlson Comorbidity Index (CCI)    0.64 (1.1) 
Baseline number of hospitalizations    0.39 (0.99) 
No. of breast-cancer-related follow-up visits   2.16 (2.69) 
 Frequency 
(%) 
Age at diagnosis  
            <65   66 (7.0%) 
              65 to 74 366 (38.7%) 
              75 to 84  404 (42.7%) 
             ≥ 85 110 (11.6%) 
Race  
           White 918 (97.0%) 
           Non-white   28 (3.0%) 
Marital status  
          Married 394 (41.6%) 
          Not married 552 (58.4%) 
State   
          KY 113 (11.9%) 
          NC 190 (20.1%) 
          OH 176 (18.6%) 
          PA 467 (49.4%) 
Annual median household income, quartile  
           Low 237 (25%) 
           Second 236 (25%) 
           Third 237 (25%) 
           High 236 (25%) 
Dual Medicare and Medicaid eligibility status  
          Dual eligible 174 (18.4%) 
          Medicare only  772 (81.6%) 
Stage   
          Stage I 524 (55.4%)  
          Stage II 327 (34.6%) 
          Stage III   95 (10.0%) 
Tumor size   
         <1cm  189 (20.0%) 
           1-2cm  446 (47.1%) 
         >2cm  299 (31.6%) 
           Unknown   12 (1.3%) 
Lymph nodal status  
           Negative 690 (72.9%) 
           Positive  256 (27.1%) 
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 Frequency 
(%) 
Commission on Cancer (CoC) accreditation  
           Yes 622 (65.7%) 
           No 297 (31.4%) 
           Unknown   27 (2.9%) 
Facility beds  
         <100  129 (13.6%) 
           100-199  179 (18.9%) 
         ≥ 200 611 (64.6%) 
           Unknown   27 (2.9%) 
Facility ownership  
           For profit   44 (4.6%) 
           Government organization    79 (8.4%) 
           Non-profit  791 (83.6%) 
           Others or unknown    32 (3.4%) 
Provider’s specialty  
           Oncologist 250 (26.4%) 
           General practitioner 573 (60.6%) 
           Others 123 (13%) 
Provider’s graduation year  
           Before 1980 361 (38.2%) 
           1980s 405 (42.8%) 
           After 1989 180 (19.0%) 
Breast cancer surgery type  
           Breast conserving surgery (BCS) 598 (63.2%) 
           Mastectomy 348 (36.8%) 
Radiation therapy  
           Yes 350 (37.0%) 
           No 596 (63.0%) 
Chemotherapy  
           Yes 477 (50.4%) 
           No 469 (49.6%) 
Timeliness of primary treatment initiation   
           Timely treatment (surgery within 60 days following diagnosis) 883 (93.3%) 
           Delayed treatment (surgery beyond 60 days after diagnosis)   63 (6.7%) 
SD = Standard Deviation 
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Table 4.3 Predictors of receiving guideline-recommended adjuvant endocrine 
therapy (AET) among Appalachian women with breast cancer: multivariate 
logistic regression (N = 946) 
Variable Guideline-recommended 
AET 
 Odds Ratio (95% CI) 
Percentage of less than high school graduate among persons 
aged 25 and over (%) 
1.04 (0.98, 1.10) 
Percentage of at least a bachelor's degree among persons aged 
25 and over (%) 
1.01 (0.98, 1.04) 
Infant death rate per 1,000 births 0.80 (0.57, 1.12) 
Annual age-adjusted, cancer-related death rate per 100,000 
population 
1.00 (0.99, 1.02) 
Average travel time to the three closest mammography centers 
(minute) 
0.98 (0.96, 0.99)* 
Baseline Charlson Comorbidity Index (CCI)  0.92 (0.80, 1.06) 
Baseline number of hospitalizations  1.02 (0.87, 1.18) 
No. of breast cancer related follow-up visits 1.00 (0.93, 1.06) 
ARC's county economic status  
            Distressed  Reference 
            At risk 0.56 (0.28, 1.11) 
            Others 0.56 (0.26, 1.20) 
Urban-rural classification  
            Metropolitan       0.81 (0.55, 1.20) 
            Non-metropolitan Reference 
Health Professional Shortage Area (HPSA) designation   
            Entirely within a HPSA Reference 
            Partially within in a HPSA 0.88 (0.50, 1.57) 
            Not within a HPSA 1.12 (0.59, 2.14) 
Age at diagnosis  
            <65 0.79 (0.43, 1.47) 
              65 to 74 Reference 
              75 to 84  1.09 (0.80, 1.50) 
             ≥ 85 1.05 (0.63, 1.75) 
Marital status  
          Married 0.63 (0.46, 0.85)** 
          Not married Reference 
State   
          KY 0.54 (0.25, 1.16) 
          NC 0.91 (0.32, 2.58) 
          OH 0.60 (0.39, 0.94)* 
          PA Reference 
Annual median household income, quartile  
          Low Reference 
          Second 1.00 (0.68, 1.49) 
          Third 1.12 (0.75, 1.68) 
          High 0.97 (0.64, 1.48) 
Dual Medicare and Medicaid eligibility status  
          Dual eligible 4.24 (2.76, 6.53)** 
          Medicare only  Reference 
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Variable Guideline-recommended 
AET 
 Odds Ratio (95% CI) 
Stage   
          Stage I 1.35 (0.55, 3.31) 
          Stage II 1.16 (0.67, 2.02) 
          Stage III Reference 
Tumor size   
         <1cm  Reference 
           1-2cm  1.23 (0.84, 1.78) 
         >2cm  0.94 (0.50, 1.78) 
           Unknown 0.41 (0.11, 1.53) 
Lymph nodal status  
           Negative Reference 
           Positive  1.18 (0.70, 1.96) 
Commission on Cancer (CoC) accreditation  
           Yes 0.90 (0.66, 1.25) 
           No Reference 
           Unknown 0.62 (0.24, 1.54) 
Provider’s specialty  
           Oncologist 1.19 (0.85, 1.67) 
           General practitioner Reference 
           Others 1.07 (0.68, 1.70) 
Provider’s graduation year  
           Before 1980 0.92 (0.67, 1.27) 
           1980s Reference 
           After 1989 1.06 (0.72, 1.55) 
Breast cancer surgery type  
           Breast conserving surgery (BCS) Reference 
           Mastectomy 1.17 (0.83, 1.65) 
Radiation therapy  
           Yes 1.19 (0.84, 1.69) 
           No Reference 
Chemotherapy  
           Yes 1.05 (0.78, 1.41) 
           No Reference 
Timeliness of primary treatment initiation   
           Timely treatment (surgery within 60 days) Reference 
           Delayed treatment (surgery beyond 60 days) 0.86 (0.47, 1.54) 
95% CI = 95% confidence interval, ARC = Appalachian Regional Commission 
*p < 0.05, **p < 0.01 
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CHAPTER 5 
DISSERTATION MANUSCRIPT TWO 
MEDICATION USE OUTCOMES ASSOCIATED WITH ADJUVANT ENDOCRINE 
THERAPY (AET) AMONG APPALACHIAN BREAST CANCER SURVIVORS 
 
Abstract 
Background: There is a paucity of literature systemically examining the effects of 
access to cancer care resources on AET use behaviors, especially in underserved 
regions such as the Appalachian region in the United States, where gaps in healthcare 
access are well documented. The objectives of this study were to explore AET 
adherence and persistence in Appalachia, delineate the effects of access to care cancer 
on adherence/persistence, and evaluate the influences of adherence and persistence 
on overall survival. 
Methods: We linked female breast cancer patients identified in cancer registries from 
the Appalachian counties in four states (KY, NC, OH, and PA) to 2006-2008 Medicare 
claims data. We included patients with invasive, non-metastatic, hormone-receptor-
positive breast cancer who received guideline-recommended AET. Eligible patients 
were followed from the initiation of AET until death or the end of the observation period. 
Medication adherence was defined as corresponding to a Medication Possession Ratio 
(MPR) ≥ 0.8 and logistic regression was utilized to assess predictors of adherence. 
Medication non-persistence was defined as the discontinuation of drugs after exceeding 
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a 60-day medication gap, and multivariate adjusted estimates of non-persistence were 
obtained using the Cox proportional hazards (PH) model. 
Results: About 31% of the total 428 patients were not adherent to AET, and 30% were 
not persistent over an average follow-up period of 421 days. Tamoxifen, relative to 
aromatase inhibitors, was associated with higher odds of adherence (OR = 2.82, p < 
0.001) and a lower risk of non-persistence (HR = 0.40, p < 0.001). Drug-related side 
effects like pain may be an important factor leading to non-adherence and early 
discontinuation. In addition, AI adherence and persistence were significantly influenced 
by out-of-pocket drug costs, dual eligibility status, and coverage gaps. Non-adherence 
to and non-persistence with AET were associated with higher risks of all-cause 
mortality, after controlling for other factors. 
Conclusion: Our findings of suboptimal AET adherence/persistence in Appalachia as 
well as positive associations between AET adherence/persistence and overall survival 
outcomes further underscore the importance of ensuring appropriate AET use in this 
population to reduce breast cancer mortality disparities. Our findings also suggest that 
intervention strategies focusing on individualized treatment and medication-related 
factors may improve adjuvant treatment use.  
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Introduction 
Currently, surgery remains the primary treatment modality for breast cancer, but recent 
marginal gains in survival may be largely attributable to the adjuvant therapy that 
usually follows primary therapy,15–17 including adjuvant radiation, chemotherapy, 
targeted therapy, and endocrine therapy.  With the growing number of breast cancer 
survivors, breast cancer care should not only provide active treatment but also 
survivorship care such as post-treatment monitoring and risk-reducing maintenance 
behaviors.  
Adjuvant endocrine therapy (AET) is a secondary prevention therapy recommended for 
use among hormone-receptor (HR) positive breast cancer survivors for a period of five 
to ten years after surgery to reduce recurrence and improve survival.18–21 Additionally, 
patient adherence to and persistence with AET are critical in maximizing treatment 
benefits; this has been identified as a significant issue in clinical practice, with non-
adherence and non-persistence rates as high as 59% and 73%, respectively.22,23 There 
is increasing recognition in the literature that greater effort should be made to improve 
adjuvant treatment use to pursue better cancer outcomes. 
The current literature showed a broad range of adherence and early discontinuation 
rates ranging from 41% to 95.7% and 12% to 73%, respectively.22,23 Variations in 
adherence and persistence in these studies may be attributable to heterogeneity in 
methodology and study population. There is no gold standard method for measuring 
adherence and persistence of AET in clinical practice, nor is there a good biomarker 
available to measure the use of tamoxifen or aromatase inhibitors (AIs).124 Therefore, 
almost all relevant studies used indirect methods to measure adherence and 
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persistence, namely pharmacy claims/medical records data, or physician report/patient 
self-report data. In general, studies that used physician report or patient self-report data 
showed better results, with adherence rates ranging from 77% to 94.7%125–127 and non-
persistence rates ranging from 21% to 31%.118,125,128,129 Most studies on AET adherence 
and persistence analyzed medical and pharmacy claims data. In these retrospective 
claims data studies, adherence was usually defined as Medication Possession Ratio 
(MPR) ≥80%, while non-persistence/discontinuation was operationalized as the 
discontinuation of drugs after exceeding a permissible gap,130 which ranged from 45 to 
180 days depending on the study.22 The discrepancies in persistence definitions may 
result in variations in discontinuation rates.  
In addition, factors that were consistently shown to be negatively associated with AET 
adherence or persistence included extreme age, increasing out-of-pocket costs of AET, 
seeing a general practitioner vs. an oncologist during follow-up care, switching between 
drugs, and treatment-associated side effects.22,23,140 However, there are very few 
studies that systemically examine the effects of access to cancer care resources on 
AET use behaviors, especially in underserved regions where patients suffer from the 
deficiencies of access to care, such as the Appalachian region. Additionally, in clinical 
practice, the literature regarding direct therapeutic outcomes associated with AET 
adherence and persistence remains underdeveloped. Most available studies controlled 
for individual-level characteristics such as demographics and cancer clinical status. 
Given the existing cancer disparities, relatively poor access to care, and lack of adjuvant 
cancer treatment use research on Appalachia’s cancer patient population, it becomes 
important to investigate the relationship between AET adherence/persistence and 
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cancer survival among Appalachian breast cancer survivors, after controlling for access 
factors. In this way, we can better understand the marginal effects of AET use outcomes 
on cancer survival after teasing out the influences of poor access to care on survival. 
Therefore, the objectives of this study were to: 1) describe the prevalence of adherence 
to and persistence with AET among Appalachian breast cancer survivors; 2) assess the 
effects of access to cancer care resources on AET adherence and persistence; 3) 
evaluate the influences of AET adherence and persistence on survival after controlling 
for access factors. 
 
Methods 
1. Study design and data source  
To achieve the study objectives, we conducted a retrospective cohort study among 
female breast cancer survivors living in the Appalachian counties of four states (PA, 
OH, KY and NC). The study time was from January 1, 2006 to December 31, 2008. The 
overall study design comprises three main periods: the baseline period (one year before 
the first breast cancer diagnosis), the diagnosis-to-AET period (the interval between the 
first diagnosis and the initiation of AET), and the follow-up period (from the date of the 
first AET prescription filled until death or the end of the observation period, 12/31/2008). 
Multiple data sources were integrated for final analyses: individual characteristics from 
cancer registries and Medicare claims data; system-level characteristics from the 
Appalachian Regional Commission (ARC) data reports, the 2010 U.S. census, the Area 
Resource File, the National Center for Health Statistics (NCHS), Centers for Disease 
Control and Prevention (CDC), and the National Cancer Institute (NCI); and 
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provider/facility characteristics mainly from Medicare Provider of Service files and 
Medicare Physician Identification and Eligibility Records files. First, we linked women 
who were diagnosed with breast cancer during 2006-2008 and tracked in the four states’ 
cancer registries to Medicare claims data using patient identifiers including name, social 
security number, gender, and birthdate. Then, the cross-link was established between 
patient data and system-level characteristics using county codes. The Unique Physician 
Identification Numbers (UPIN) and National Provider Identifiers (NPI) were utilized to 
link patient claims to provider/facility factors. The time frame of these data sources was 
in accordance with our study time period. The final dataset for statistical analyses had 
completely de-identified information. Data use was approved by the Centers for 
Medicare and Medicaid services (CMS) and cancer registries, and the study was 
approved by the University of Michigan’s Institution Review Board (IRB).  
 
2. Study population  
We included adult women who lived in the Appalachian counties of the four states and 
were diagnosed with confirmed stage I-III, hormonal receptor (HR) positive, primary 
breast cancer in 2007. Other inclusion criteria were continuous enrollment in Medicare 
Parts A, B and D, recorded history of primary breast cancer treatment, eligibility for AET, 
and no AET use before the primary breast cancer treatment. Patients who were enrolled 
in a Health Maintenance Organization (HMO) or Medicare Advantage Program or had 
conflicting information across data sources were excluded from the study. Then we 
extracted a subset group of subjects who received guideline-recommended AET, which 
referred to the receipt of AET within one year following diagnosis.167 To facilitate the 
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measurement of medication adherence and persistence, we ensured that we followed 
patients for a period of at least 6 months. Our final study sample comprised 428 
subjects. 
 
3. Outcome measures 
3.1 Adherence 
We calculated AET adherence for each individual using the MPR. The MPR is a 
commonly used medication adherence measure using administrative claims data that 
has been adopted in a great deal of AET adherence research.22,23 It is defined as the 
ratio of the amount of days for which the drug was dispensed divided by the number of 
days for which drug was needed,168,169 which was determined in this study using the 
following equation170,171:  
 
Medication possession ratio (MPR) = number of days’ supply / (number of follow-up 
days ─ number of inpatient days) 
 
Additionally, the MPR was truncated between 0 and 1.2, as well as dichotomized into 
adherence and non-adherence using the conventional cut-off point of 0.8 (0 ≤ MPR < 
0.8: non-adherence; 0.8 ≤ MPR ≤ 1.2: adherence). For those who switched between 
tamoxifen and AI, we precluded any double-counting of the days when the patient took 
both tamoxifen and AI. The non-adherence rate refers to the percentage of patients who 
were not adherent. 
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3.2 Persistence 
Medication persistence is defined as the act of complying with a provider’s 
recommendations to use medications for a prescribed length of time130 and is commonly 
operationalized in retrospective claims data studies as the discontinuation of drugs after 
exceeding a permissible gap.130 In AET persistence research, the prescription fill gap 
has been defined as ranging from 45 to 180 days, based on the pharmacological 
characteristics of the drugs; legitimate delays in refills, such as hospitalization; and the 
length of the follow-up period.27,122,123,125,131–133 Taking all of the above into 
consideration, we decided to define AHT non-persistence as a minimum 60-day 
medication fill gap. Patients who switched drugs within 60 days were still considered 
persistent. The non-persistence rate (also referred to as early discontinuation rate) 
refers to the percentage of patients who were not persistent. 
 
3.3 Survival 
Overall survival was defined as the period from AET initiation until death. The follow-up 
period ended on December 31, 2008.  
 
4 Covariate measures 
The access factors examined in this study included county economic status, county-
level educational attainment (percentages of persons with less than high school 
education and at least a bachelor's degree), urban or rural geographic residence, 
county-level infant and cancer mortality rates, Health Professional Shortage Area 
(HPSA) designation, age at diagnosis, marital status, state of residence, four quartiles 
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of annual median household income (at the census block group level), dual Medicare 
and Medicaid eligibility indicator, average travel time from the patient to the three closes 
mammography centers, breast cancer stage, tumor size, lymph nodal status, patients’ 
comorbidities, treatment facility’s Commission on Cancer (CoC) accreditation status, 
number of beds, facility type, ownership, the provider’s specialty and graduation year, 
the number of breast-cancer-related follow-up visits, and timeliness of primary treatment 
initiation. We also assessed the type of breast cancer treatments received such as 
surgery type, radiation therapy and chemotherapy, as well as the type of AET received 
(tamoxifen, AIs, or switching between tamoxifen and AIs). We included commonly used 
AIs in this study, which were anastrozole, letrozole, and exemestanes.  
For a better assessment of the adherence/persistence issue, we also included the 
average monthly out-of-pocket drug costs, whether patients reached the out-of-pocket 
threshold and began to receive catastrophic coverage, and the following medication-
related factors: 1) the number of unique prescription drugs co-administered during 
the follow-up period, as a proxy measure of pill burden, was identified using NDC from 
the Medicare Part D claims data; 2) the season at the initiation of AET (spring, 
summer, fall, winter) was also included in analyses because the seasonal weather 
condition may have influences on travel and transportation, which in turn may affect 
patient behaviors of picking up their drugs. And the seasonal effects may be more 
phenomenal in a largely rural and mountainous environment such as Appalachia; 3) 
AET-associated side effects: we utilized proxy measures for AET-associated side 
effects (e.g., osteoporosis, hot flashes/night sweats, arthralgia) using the indicators of 
the use of evidence-based pharmacological treatments (prescription drugs) for them. As 
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per clinical recommendations for managing AET associated side effects,174–176 we 
created dummy variables indicating  whether or not patients used antidepressants 
(fluoxetine, paroxetine, venlafaxine, citalopram, gabapentin), bisphosphonates 
(zoledronic acid, alendronate, risedronate), and pain medications (opioids, gabapentin, 
pregabalin) during the follow-up period.  
 
5 Statistical analyses 
5.1 Descriptive analyses and bivariate association analyses 
We conducted descriptive analyses of the access variables, medication-related factors, 
type of breast cancer treatment, and follow-up days using means for continuous 
variables and frequencies and percentages for binary and categorical variables. We 
assessed MPRs, adherence rates, and discontinuation rates among the three AET 
groups. We used the 2×2 contingency table and phi coefficient to assess the correlation 
between AET adherence and persistence. Preliminary bivariate association analyses 
were conducted to find potential predictors of adherence, persistence, and survival. We 
conducted two-tailed t-tests for continuous predictors of adherence and chi-square tests 
for binary and categorical predictors of adherence. We used Kaplan-Meier survival 
curves and log-rank tests to assess the associations between each binary/categorical 
variable and persistence or survival time, as well as univariate Cox regression analyses 
to evaluate the relationships between each continuous variable and persistence or 
survival time. In particular, we utilized Kaplan-Meier survival curves and log-rank tests 
to assess the bivariate associations between AET adherence/persistence and overall 
survival. 
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5.2 Multivariate analysis of AET adherence 
Multivariate logistic regression was used to assess the relationship between access to 
cancer care and AET adherence. For the sake of parsimony, we incorporated potentially 
significant predictors with a p value less than 0.25 in the bivariate association analyses 
into the final multivariate logistic model with a robust standard error. For the final logistic 
model of adherence, we also tested the significance of the categorical variables and 
checked the goodness-of-fit, multicollinearity, and c- statistic. Model selection was 
based on likelihood ratio tests, Akaike's information criterion (AIC) and Bayesian 
information criterion (BIC). The potential random effects of clustered county- and state- 
level factors were also tested by using the multilevel mixed-effects logistic regression. 
 
5.3 Multivariate analysis of AET persistence 
We obtained multivariate adjusted estimates of non-persistence (discontinuation) using 
the Cox proportional hazards (PH) model. We included in the final model only those 
predictors for which p < 0.25 in the bivariate association analyses. We utilized the Efron 
method to handle ties. We checked the proportional hazard assumption of the variables 
in the final model by using the Schoenfeld and scaled Schoenfeld residuals. If a variable 
did not meet the assumption, we estimated a stratified Cox model based on the 
variable.121  
 
5.4 Multivariate analysis of all-cause mortality 
We utilized Cox PH models to assess whether AET adherence and persistence 
influence all-cause mortality among our study population. In the models, we also 
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adjusted the potential predictors with a p value less than 2.5 in the bivariate association 
analyses. We checked the proportional hazard assumptions by using the Schoenfeld 
and scaled Schoenfeld residuals and the goodness-of-fit by using the Cox-Snell 
residuals.  
 
5.5 Sensitivity analyses 
Sensitivity analyses were also conducted to reduce the potential errors or uncertainty 
caused by the definitions of adherence and persistence, as well as to achieve a better 
understanding of the relationships. AET adherence and persistence were re-defined 
using MPR cutoff points ranging from 0.6 to 0.9 and a 90-day medication fill gap, 
respectively.  
The statistical significance level was set to p < 0.05. We used R 3.0.2 for general data 
management, ArcGIS 10.1 for geo-related data management, and Stata 13 for 
analyses.  
 
Results 
Our final study sample consisted of 428 Medicare-enrolled women with breast cancer 
living in the 125 Appalachian counties of four states (KY, NC, OH, and PA) who initiated 
AET within one year after the breast cancer diagnosis. Eligible patients were followed 
for a period of 181 to 706 days, with a mean of 421 days and a median of 411 days. 
The mean MPR for all subjects was 0.83, and approximately 69.4% were considered 
adherent to AET (shown in Table 5.1). The average AET persistence time was 347.6 
days, and the early discontinuation rate was about 30.1%. The tamoxifen group had 
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better adherence and persistence than the AI group (mean MPR: 0.86 vs. 0.82; mean 
persistence time: 370.8 days vs. 338.9). AET adherence and persistence were found to 
be highly correlated (Phi coefficient = 0.81). In addition, when medication adherence 
was re-defined using MPRs ranging from 0.6 to 0.9, adherence rates varied from 83.2% 
to 55.1%, with the largest differences at the cutoff points of 0.7 and 0.9.  The adherence 
rates at the cutoff points of 0.7 and 0.9 were 78.5% and 55.1%, respectively. If a 90-day 
medication fill gap was used to define non-persistence, the difference in the mean 
persistence times was moderately small (347.6 days for the 60-day fill gap vs. 366.4 
days for the 90-day fill gap).  
Table 5.2 describes county-level characteristics. The results confirmed the deficiencies 
in access to care in Appalachia including economically distressed or at risk populations 
(43.2%), largely rural environments (67.2%), and healthcare professional shortages 
(88%), as well as community educational levels and infant and cancer mortality rates 
that were worse than national averages. Bivariate association analyses showed that 
adherent and persistent patients were more likely to live in counties with a lower infant 
mortality rate (p = 0.048 and p = 0 .245, respectively). But, overall, we did not find 
bivariate associations with strong significance between county-level factors and 
adherence/persistence.  
Table 5.3 presents the descriptive analysis results of individual, facility/provider, and 
medication-related characteristics. During the follow-up period, eligible patients had 
2.25 breast-cancer-related follow-up visits, on average. Patients seem to suffer from 
substantial pill burdens. An average of approximately 11.6 prescription drugs was co-
administered to patients during follow-up; the estimated average monthly out-of-pocket 
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drug costs were about $50.00. Approximately 26.4% of the population even reached the 
catastrophic coverage threshold. Moreover, the use rates of antidepressants, 
bisphosphonates, and pain medications that can treat AET-associated side effects were 
about 9.1%, 21.5%, and 10%, respectively. Dual eligibility status, catastrophic 
coverage, lymph nodal status, and use of pain medications had significant bivariate 
associations with AET adherence and persistence (p < 0.05).  
Table 5.4 and Table 5.5 show factors significantly associated with AET adherence and 
discontinuation: AET drug class, catastrophic coverage, and use of pain medications. 
Please note that because dual eligibility status and provider specialty did not meet the 
proportional hazard assumption, our final Cox PH model of AET discontinuation was 
stratified by these two variables (see in Table 5.5). Patients receiving catastrophic 
coverage benefits had about three-fold odds of adhering to AET (OR = 3.25, p = 0.001) 
and a 44% lower risk of discontinuing AET (Hazard Ratio = 0.56, p = 0.03). Co-
administration of pain medications was associated with 68% reduced odds of 
adherence to AET (OR = 0.32, p = 0.003) and an estimated 2.5 times increased risk of 
AET non-persistence (Hazard Ratio = 2.47, p = 0.002). Tamoxifen was associated with 
greater likelihood of adherence (OR = 2.82, p = 0.003) and a lower risk of non-
persistence (Hazard Ratio = 0.40, p = 0.002) than AIs. 
In addition, to better evaluate the factors associated with adherence and persistence, 
we stratified our population into those who took tamoxifen and those who took AIs and 
re-estimated the models. We found that increased out-of-pocket costs were associated 
with reduced likelihood of adherence in the AI group (OR = 0.99, p = 0.008), but the 
results were not significant in the tamoxifen group. Those dual-eligible enrollees who 
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qualified for low-income subsidies (LIS) did not experience the drug coverage gap 
experienced by Medicare-only enrollees; we did not find that receiving catastrophic 
coverage benefits significantly affected AET adherence or persistence among these 
dual-eligible enrollees. For Medicare-only enrollees, however, receiving catastrophic 
coverage significantly improved AI adherence (OR = 6.20, p = 0.001) and persistence 
(Hazard Ratio = 0.31, p = 0.01) but did not have significant impacts on tamoxifen use. In 
terms of side effects, we found that using pain medications was significantly associated 
with poor adherence (OR = 0.41, p = 0.03) and persistence (Hazard Ratio = 1.94, p = 
0.05) to AI but not to tamoxifen.  
The results of using differing definitions of adherence and persistence in our sensitivity 
analyses showed that AET drug class and catastrophic coverage were robust predictors 
of AET adherence while AET drug class and the use of pain medication were stable 
predictors of AET persistence. Moreover, when we used a 0.9 cut-off point to define 
adherence, the provider’s specialty and primary treatment type became significantly 
correlated with adherence, as well. And if a 90-day medication gap was used to 
determine persistence, positive lymph nodal status was significantly associated with a 
lower risk of early discontinuation (HR = 0.47, p = 0.015).  
During the study period, all-cause death occurred in 15 patients (3.5% of our sample). 
Figures 5.2 and 5.3 show the Kaplan-Meier survival curves by AET medication 
adherence and persistence. From the graphs, we can see that patients who were not 
adherent to or persistent with AET had a higher risk of death, both with significant log 
rank test results (p = 0.04 and 0.01, respectively). Multivariate adjusted Cox PH models 
also supported these findings (shown in Tables 5.6 and 5.7). Other significant factors 
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associated with increased risk of all-cause death were increased age and being treated 
in non-CoC accredited facilities. The conclusions did not differ if we changed the 
definitions of adherence and persistence. 
 
Discussion 
Our study is among the first to delineate the manner in which multidimensional 
determinants of access to cancer care affect patient medication use behaviors, 
specifically, adherence to and persistence with adjuvant treatments, in Appalachia. The 
AET adherence rate and early discontinuation rate in the first two years among 
Appalachian women with invasive, non-metastatic, hormone-receptor-positive breast 
cancer were 69% and 30%, respectively. We found that adherence rates in previous 
studies using US pharmacy claims data were in the range of 70%-80%,116,117,138,139 and 
the discontinuation rates were fairly consistent at around 20%.27,28,117,123 There were 
only two extreme results: one was a 60% adherence rate among Medicaid enrollees in 
North Carolina, one of the Appalachian states27; the other was a 90% adherence rate 
among patients using mail-order pharmacy services.28 Overall, AET adherence and 
persistence seems to be lower in Appalachia compared to the rest of the US. 
Our findings suggested that adherence to and persistence with AET were primarily 
related to the medication-related factors. Our results consistently showed that tamoxifen 
was associated with better medication use outcomes than AIs, which may be 
attributable to different adverse effect profiles and drug costs. The use of pain 
medications, presumably to treat AI-related musculoskeletal pain, was significantly 
correlated with poor adherence and persistence, which may partially explain the worse 
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medication use outcomes associated with AIs. Other research showed that AET-
induced side effects like musculoskeletal pain may increase physical burden on 
patients, cause misbeliefs about AET use, and adversely affect patients’ intentions to 
adhere to the medication.177,178 Our study supports this conclusion and highlights the 
need to develop interventions that focus on individualized side-effect management and 
better patient education about AET use.  
In addition, tamoxifen generally involves lower costs to both patients and third-party 
payers than AIs, so it may be associated with reduced financial burden in the long run. 
We found a negative relationship between out-of-pocket costs and adherence among 
patients who used AIs only (OR = 0.99, p = 0.008) but did not find a significant 
relationship among those who used tamoxifen only. The relationship may be influenced 
by several factors: type of Medicare healthcare plan, dual eligibility status that can 
determine the qualification for LIS, whether patients enter the coverage gap, and 
whether patients receive catastrophic coverage benefits beyond the out-of-pocket 
threshold. Riley et al (2011) found that adherence rates did not differ much between 
patients with and without LIS in the tamoxifen group, but adherence to AIs was 
significantly improved if patients received LIS.116 In the present study, however, we did 
not establish a similar significant interaction between AET drug class and dual eligibility 
status to predict adherence or persistence. Previous research found that AET 
adherence declined when Medicare-only patients without LIS entered in the coverage 
gap compared to pre-coverage gap116; our study further found that AI adherence and 
persistence improved significantly after these patients got out of the coverage gap and 
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received catastrophic coverage benefits, but we found no significant changes in 
tamoxifen adherence and persistence in the same circumstances.  
To our knowledge, our study is also one of the first to assess the effects of AET 
adherence and persistence on survival in an underserved region like Appalachia. Even 
with the constraints of small sample size and short follow-up time, we found significant 
positive relationships between non-adherence/non-persistence to AET and all-cause 
mortality. Hershman et al (2011) found that non-persistence and non-adherence to AET 
were significantly associated with increased hazard of all-cause death by 26% and 49%, 
respectively.122 Similarly, McCowan et al (2008) identified a 10% increase in the hazard 
of all-cause mortality among those who were not adherent to tamoxifen, compared to 
those who were adherent, as well as a significantly lower risk of death associated with 
use of tamoxifen over a longer duration.137 These findings may imply the importance of 
ensuring appropriate AET use in the pursuit of additional gains in survival. It is also 
noteworthy that AET adherence and persistence may have different influences on 
survival. By definition, AET persistence emphasizes more on the recommended length 
of time, which was determined by clinical evidence of benefits in breast cancer 
outcomes.24,25 AET adherence focuses on whether patients can use AET everyday as 
recommended to keep a steady drug level that is warranted to maximize the drug 
effectiveness and improve clinical outcomes. However, long follow-up time that can 
cover the whole recommended clinical course of AET may be needed to differentiate 
the effects of AET adherence and persistence on breast cancer outcomes.  
This study had several limitations. First, given the inherent characteristics of 
retrospective cohort studies, we could not establish causality. Second, the relatively 
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short length of the follow-up period and the small sample size limited our ability to 
conduct further analyses. For example, an adequate number of death cases would 
allow us to study breast-cancer-related survival, while a longer study period would give 
us the opportunity to look at changes in adherence and persistence over the whole 
recommended clinical course of AET (5 to 10 years). Third, we did not include some 
detailed information and important potential confounders, such as accurate drug 
indications, drugs used in hospice settings, prescribers’ characteristics, pharmacy type, 
and patient attitudes and beliefs about long-term AET use. Fourth, when using 
administrative claims data to assess medication adherence/persistence, we assumed 
that the claims were billed in an accurate and timely manner, AET was obtained only 
through Medicare Part D, and the medication was actually taken by the patients. These 
assumptions may not always be true under all circumstances, which may cause 
measurement errors. For example, patients might obtain AET from other sources than 
through Medicare Part D, which may not be captured in our dataset especially when in 
the coverage gap. Dually eligible patients may receive additional benefits from their 
Medicaid programs to help with their out-of-pocket money, which were not considered in 
our calculation of out-of-pocket drug costs. Finally, our target population was Medicare 
enrollees with breast cancer who lived in the Appalachian region and was first-time 
users of tamoxifen and AIs, which were used only for adjuvant treatment purposes. We 
did not study ovarian suppression/ablation, or the use of tamoxifen or AIs as primary 
treatments or neoadjuvant therapy for breast cancer, or AET use in a general breast 
cancer patient population, which is typically younger than our study population. These 
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may limit the generalizability of our study findings and suggest the need for future 
research efforts. 
 
Conclusion 
AET adherence and persistence are suboptimal in Appalachia. They differ between 
drug classes possibly as a result of distinct adverse effect profiles and differences in 
patient affordability stemming from drug costs and health plan benefits. Additionally, we 
confirm the substantial benefits of adherence to and persistence with AET in achieving 
the advancement of overall survival. Therefore, this study suggests the value of adding 
a component focusing on medication management related to AET use to current cancer 
care models in Appalachia with the ultimate goal of reducing breast cancer mortality 
disparities. 
 
 
Table 5.1 Prevalence of adjuvant endocrine therapy (AET) adherence and 
persistence among Appalachian women with invasive, non-metastatic, hormone-
receptor positive breast cancer  
 
Group 
MPR, mean 
(SD) 
Adherence 
rate, n (%) 
£
 
Persistence time 
(day), mean (SD) 
Discontinuation 
rate, n (%) 
£
 
All subjects (N = 428) 0.83 (0.24) 297 (69.4%) 347.6 (165.5) 129 (30.1%) 
Tamoxifen group (N = 
80) 
0.86 (0.26) 63 (78.8%) 370.8 (168.9) 15 (18.8%) 
Aromatase inhibitor 
group (N = 319) 
0.82 (0.24) 212 (66.5%) 338.9 (163.0) 105 (32.9%) 
Switching group (N = 
29) 
0.85 (0.20) 22 (75.9%) 378.8 (179.1) 9 (31.0%) 
SD = Standard Deviation, MPR = Medication Possession Ratio 
£ 
The denominator of the percentage was the number of patients in the specific subgroup.   
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Table 5.2 Descriptive statistics of system-level characteristics (by county) (N = 
125) 
 
Variables Mean (SD) 
Percentage of less than high school graduate among persons 
aged 25 and over (%) 
  18.8 (7.7) 
Percentage of at least a bachelor's degree among persons aged 
25 and over (%) 
  15.9 (6.4) 
Infant death rate per 1,000 births     7.2 (0.85) 
Annual age-adjusted, cancer-related death rate per 100,000 
population 
197.7 (28.8) 
 Frequency (%) 
ARC's county economic status  
            Distressed  30 (24.0%) 
            At risk 24 (19.2%) 
            Others 71 (56.8%) 
Urban-rural classification  
            Metropolitan       41 (32.8%) 
            Non-metropolitan 84 (67.2%) 
Health Professional Shortage Area (HPSA) designation   
            Whole county in HPSA 40 (32.0%) 
            Part county in HPSA 70 (56.0%) 
            Not in HPSA 15 (12.0%) 
SD = Standard Deviation, ARC = Appalachian Region Commission 
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Table 5.3 Descriptive statistics of individual, facility/provider, and medication-
related characteristics of final study population (N = 428) 
 
Variables Mean (SD) 
Average travel time to the three closest mammography centers (minute) 15.9 (10.2) 
Baseline Charlson Comorbidity Index (CCI)    0.63 (0.95) 
Baseline number of hospitalizations    0.38 (0.97) 
No. of breast-cancer-related follow-up visits   2.25 (2.44) 
Average monthly out-of-pocket costs (US dollar) 50.0 (64.2) 
No. of unique prescription drugs co-administered 11.6 (6.24) 
Follow-up time (day) 421.2 (116.3) 
 Frequency (%) 
#
 
Age at diagnosis   
            <65   35 (8.2%) 
              65 to 74 155 (36.2%) 
              75 to 84  187 (43.7%) 
             ≥ 85   51 (11.9%) 
Marital status  
          Married 140 (32.7%) 
          Not married 288 (67.3%) 
State   
          KY   61 (14.3%) 
          NC   77 (18.0%) 
          OH   75 (17.5%) 
          PA 215 (50.2%) 
Annual median household income (US dollar), quartile  
          Low ($9,768 - $31,408.5) 107 (25%) 
          Second ($31,408.5 - $ 41,552) 107 (25%) 
          Third ($41,552 - $51,577.5) 107 (25%) 
          High ($51,577.5 - $15,0625) 107 (25%) 
Dual Medicare and Medicaid eligibility status  
          Dual eligible 121 (28.3%) 
          Medicare only  307 (71.7%) 
Catastrophic coverage indicator  
          Yes 113 (26.4%) 
          No 315 (73.6%) 
Stage   
          Stage I 239 (55.8%) 
          Stage II 149 (34.8%) 
          Stage III   40 (9.4%) 
Tumor size   
         <1cm    84 (19.6%) 
           1-2cm  215 (50.2%) 
         >2cm  129 (30.1%) 
Lymph nodal status  
           Negative 312 (72.9%) 
           Positive  116 (27.1%) 
Commission on Cancer (CoC) accreditation  
           Yes 272 (63.6%) 
           No  156 (36.4%) 
Facility beds  
         <100    70 (16.4%) 
           100-199    91 (21.3%) 
         ≥ 200 267 (62.4%) 
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 Frequency (%) 
#
 
Facility ownership  
           Non-profit  364 (85.0%) 
           Others    64 (15.0%) 
Provider’s specialty  
           Oncology 116 (27.1%) 
           General practitioner 259 (60.5%) 
           Other   53 (12.4%) 
Provider’s graduation year  
           Before 1980 163 (38.1%) 
           1980s 186 (43.5%) 
           After 1989   79 (18.5%) 
Breast cancer surgery type  
           Mastectomy 166 (38.8%) 
           Breast conserving surgery (BCS) + radiation 139 (32.5%) 
           BCS, no radiation 123 (28.7%) 
Chemotherapy  
           Yes 215 (50.2%) 
           No 213 (49.8%) 
Timeliness of primary treatment initiation   
           Timely treatment (surgery within 60 days) 398 (93.0%) 
           Delayed treatment (surgery beyond 60 days)   30 (7.0%) 
Use of antidepressants  
           Yes   39 (9.1%) 
           No 389 (90.9%) 
Use of bisphosphonates  
           Yes   92 (21.5%) 
           No 336 (78.5%) 
Use of pain medications  
           Yes   43 (10.0%) 
           No 385 (90.0%) 
Season at the initiation of AET  
           Spring   97 (22.7%) 
           Summer 103 (24.1%) 
           Fall  103 (24.1%) 
           Winter 125 (29.2%) 
SD = Standard Deviation, AET = adjuvant endocrine therapy 
# Note that the percentages of some variables may not add up to 100% due to rounding errors. 
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Table 5.4 Predictors of adherence to adjuvant endocrine therapy (AET) among 
Appalachian women with breast cancer: multivariate logistic regression (N = 428) 
 
Variable Adherence to AET, Odds Ratio (95% CI) 
Percentage of at least a bachelor's degree among 
persons aged 25 and over (%) 
0.997 (0.957, 1.039) 
Infant death rate per 1,000 births 1.16 (0.66, 2.04) 
Annual age-adjusted, cancer-related death rate per 
100,000 population 
1.01 (0.99, 1.02) 
Baseline Charlson Comorbidity Index (CCI)  1.08 (0.83, 1.40) 
Average monthly out-of-pocket costs (US dollar) 0.997 (0.993, 1.001) 
Health Professional Shortage Area (HPSA) designation   
            Whole county in HPSA Reference 
            Part county in HPSA 1.19 (0.49, 2.91) 
            Not in HPSA 1.26 (0.45, 3.55) 
State   
          KY 0.39 (0.14, 1.13) 
          NC 0.43 (0.07, 2.60) 
          OH 0.66 (0.30, 1.42) 
          PA Reference 
Dual Medicare and Medicaid eligibility status  
          Dual-eligible 1.26 (0.59, 2.68) 
          Medicare-only  Reference 
Catastrophic coverage indicator  
          Yes  3.25 (1.67, 6.33)** 
          No Reference 
Lymph nodal status  
           Negative Reference 
           Positive  1.51 (0.86, 2.66) 
Commission on Cancer (CoC) accreditation  
           Yes 0.89 (0.53, 1.50) 
           No Reference 
Provider specialty  
           Oncology 1.25 (0.73, 2.16) 
           General practitioner Reference 
           Other 0.54 (0.26, 1.10) 
Breast cancer surgery type  
           Mastectomy Reference 
           Breast conserving surgery (BCS) + radiation 0.74 (0.40, 1.35) 
           BCS, no radiation 0.66 (0.36, 1.21) 
Use of bisphosphonates  
           Yes 1.39 (0.78, 2.46) 
           No Reference 
Use of pain medications  
           Yes 0.32 (0.15, 0.67)** 
           No Reference 
AET drug class  
          Tamoxifen 2.82 (1.42, 5.64)** 
          Aromatase inhibitor (AI) Reference 
          Switching between two drug classes 2.20 (0.85, 5.66) 
95% CI = 95% confidence interval         **p < 0.01 
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Table 5.5 Factors associated with discontinuation of adjuvant endocrine therapy 
(AET) among Appalachian women with breast cancer: Cox proportional hazards 
(PH) model, stratified by the provider’s specialty and the patient’s dual eligibility 
status (N = 428) 
 
Variable AET discontinuation, Hazard Ratio (95% CI) 
Percentage of at least a bachelor's degree among 
persons aged 25 and over (%) 
0.99 (0.96, 1.02) 
Infant death rate per 1,000 births 1.08 (0.90, 1.31) 
Annual age-adjusted, cancer-related death rate per 
100,000 population 
1.00 (0.99, 1.01) 
Baseline Charlson Comorbidity Index (CCI)  0.96 (0.77, 1.19) 
Age at diagnosis   
            <65 0.47 (0.16, 1.36) 
              65 to 74 Reference 
              75 to 84  1.10 (0.73, 1.66) 
             ≥ 85 1.17 (0.63, 2.19) 
Marital status  
          Married 1.13 (0.76, 1.69) 
          Not married Reference 
Annual median household income (US Dollar), 
quartile 
 
          Low ($9,768 - $31,408.5) Reference 
          Second ($31,408.5 - $ 41,552) 1.26 (0.73, 2.17) 
          Third  ($41,552 - $51,577.5) 1.06 (0.61, 1.85) 
          High ($51,577.5 - $15,0625) 1.25 (0.71, 2.20) 
Catastrophic coverage indicator  
          Yes  0.56 (0.33, 0.95)* 
          No Reference 
Lymph nodal status  
           Negative Reference 
           Positive  0.69 (0.43, 1.10) 
Commission on Cancer (CoC) accreditation  
           Yes 1.22 (0.76, 1.94) 
           No Reference 
Facility beds  
           <100 beds 1.20 (0.65, 2.21) 
          100-199 beds 0.75 (0.44, 1.28) 
           >=200 beds Reference 
Breast cancer surgery type  
           Mastectomy Reference 
           Breast conserving surgery (BCS) + radiation 1.14 (0.70, 1.86) 
           BCS, no radiation 1.50 (0.94, 2.40) 
Use of bisphosphonates  
           Yes 0.75 (0.46, 1.20) 
           No Reference 
Use of pain medications  
           Yes 2.47 (1.41, 4.33)** 
           No Reference 
AET drug class  
          Tamoxifen 0.40 (0.22, 0.71)** 
          Aromatase inhibitor (AI) Reference 
          Switching between two drug classes 0.86 (0.41, 1.80) 
95% CI = 95% confidence interval 
*p < 0.05, **p < 0.01  
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Figure 5.1 Kaplan-Meier curves of overall survival by adjuvant endocrine therapy 
(AET) adherence 
 
 
Note: The start time of survival analysis was 180 days after the initiation of AET because our study design 
only included patients who were alive for at least 180 days after the initiation of AET.  
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Figure 5.2 Kaplan-Meier curves of overall survival by adjuvant endocrine therapy 
(AET) persistence 
 
 
Note: The start time of survival analysis was 180 days after the initiation of AET because our study design 
only included patients who were alive for at least 180 days after the initiation of AET.  
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Table 5.6 The association between adjuvant endocrine therapy (AET) non-
adherence and all-cause mortality among Appalachian women with invasive, non-
metastatic and hormone receptor positive breast cancer, using Cox proportional 
hazards (PH) model (N = 428) 
 
Variable All-cause mortality, Hazard Ratio (95% CI) 
Adherence to AET  
             Yes Reference 
             No 9.15 (2.11, 39.62)** 
Age at diagnosis (year) 1.14 (1.04, 1.25)** 
Marital status  
          Married 1.75 (0.26, 11.57) 
          Not married Reference 
Dual Medicare and Medicaid eligibility status  
          Dual eligible 3.07 (0.76, 12.41) 
          Medicare only  Reference 
Stage   
          Stage I Reference 
          Stage II 1.46 (0.20, 10.40) 
          Stage III 1.25 (0.10, 16.05) 
Tumor size   
         <1cm  Reference 
           1-2cm  0.20 (0.02, 1.57) 
         >2cm  0.46 (0.04, 4.60) 
Commission on Cancer (CoC) accreditation  
           Yes 0.12 (0.02, 0.72)* 
           No Reference 
Facility beds  
           <100 beds 1.54 (0.29, 8.08) 
          100-199 beds 3.07 (0.56, 16.64) 
           >=200 beds Reference 
Breast cancer surgery type  
           Mastectomy Reference 
           Breast conserving surgery (BCS)  0.47 (0.12, 1.92) 
Baseline number of hospitalizations  0.99 (0.65, 1.49) 
No. of breast-cancer-related follow-up visits 0.56 (0.30, 1.07) 
No. of unique prescription drugs co-administered 0.97 (0.88, 1.07) 
95% CI = 95% confidence interval 
*p < 0.05, **p < 0.01 
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Table 5.7 The relationship between adjuvant endocrine therapy (AET) non-
persistence and all-cause mortality among Appalachian women with invasive, 
non-metastatic and hormone receptor positive breast cancer, using Cox 
proportional hazards (PH) model (N = 428) 
 
Variable All-cause mortality, Hazard Ratio (95% CI) 
Persistence with AET  
             Yes Reference 
             No 9.48 (2.14, 41.95)** 
Age at diagnosis (year) 1.12 (1.02, 1.22)* 
Marital status  
          Married 1.35 (0.22, 8.43) 
          Not married Reference 
Dual Medicare and Medicaid eligibility status  
          Dual eligible 2.79 (0.67, 11.57) 
          Medicare only  Reference 
Stage   
          Stage I Reference 
          Stage II 1.22 (0.17, 8.92) 
          Stage III 1.17 (0.09, 14.59) 
Tumor size   
         <1cm  Reference 
           1-2cm  0.23 (0.03, 1.71) 
         >2cm  0.42 (0.04, 4.39) 
Commission on Cancer (CoC) accreditation  
           Yes 0.11 (0.02, 0.72)* 
           No Reference 
Facility beds  
           <100 beds 1.47 (0.29, 7.54) 
          100-199 beds 2.17 (0.45, 10.37) 
           >=200 beds Reference 
Breast cancer surgery type  
           Mastectomy Reference 
           Breast conserving surgery (BCS)  0.31 (0.07, 1.45) 
Baseline number of hospitalizations  0.95 (0.62, 1.46) 
No. of breast-cancer-related follow-up visits 0.55 (0.30, 1.01) 
No. of unique prescription drugs co-administered 0.97 (0.88, 1.07) 
95% CI = 95% confidence interval 
*p < 0.05, **p < 0.01 
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CHAPTER 6 
OVERALL CONCLUSION 
This study used a large dataset that integrated cancer registries, Medicare claims, area 
population data, and facility/provider information to examine AET utilization and use 
behaviors among breast cancer survivors in four states of Appalachia. It is innovative in 
terms of establishing an approach to systemically evaluate the relationships between 
AET utilization, adherence and persistence with determinants of access to cancer care 
in an underserved region like Appalachia in which significant deficiencies of access to 
care exist. It is also significant in the sense of further exploring whether and to what 
extent adjuvant treatment use disparities could result in breast cancer survival 
disparities in Appalachia. There are several major findings in this study that may 
contribute to current evidence of this issue in the literature. 
 
6.1 Major findings 
First, we found that the Appalachian region has disadvantaged AET utilization and use 
behaviors. The prevalence of receiving guideline-appropriate AET among invasive, non-
metastatic, and HR-positive breast cancer survivors was only 47.6% in our Appalachian 
population, which was much lower than the national average rate (74%) identified in a 
nationwide Medicare population with Part D benefits by using the SEER and Medicare 
data.116 The large discrepancy may be, in part, due to significant adjuvant treatment 
disparities in Appalachia, or because of our study design that included new users who 
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used endocrine therapy for adjuvant treatment use only. Therefore, to better delineate 
this problem, future research comparing the prevalence rates in Appalachian counties 
with non-Appalachian counties in these states is definitely warranted. Moreover, the 
two-year AET non-adherence and early discontinuation rates in the Appalachian breast 
cancer patient population were 31% and 30%, respectively, which also seem to be 
inferior to the rates in non-Appalachian populations in the U.S.27,28,116,117,123,138,139 
Overall, AET use is found to be a vital and pressing issue among Appalachian breast 
cancer survivors, which calls for effective, targeted interventions to alleviate adjuvant 
treatment use disparities in this region. 
Second, inadequate medical and drug insurance coverage may be a critical barrier to 
AET access and use in the Appalachian breast cancer population. We found that the 
dual eligibility of Medicare and Medicaid determining the qualification of receipt of LIS 
was a significant factor contributing to AET use. Some breast cancer patients may not 
be poor enough to qualify for Medicaid, but the high expenses associated with cancer 
care and treatments may still be a significant financial burden to the patients and their 
families, which may make cost one of the most important determinants of access to and 
utilization of these treatments. Needless to say, there is a large indigent population in 
Appalachia. In addition, we found that adherence to and persistence with AIs were more 
likely than with tamoxifen to be influenced by out-of-pocket drug costs, dual-eligible 
status, and whether in the coverage gap. We speculate that the higher drug costs 
associated with AIs than with tamoxifen was one of the primary causes of better 
adherence and persistence with AIs than with tamoxifen in our population. The 
implementation of Part D has offered important opportunities for Medicare beneficiaries 
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to have better access to medications116 and reduced cost-related medication non-
adherence.112 Yet there may still be barriers for breast cancer patients to access and 
maintain using high-cost cancer treatments, which warrants joint efforts from different 
stakeholders to improve guideline-appropriate medication access and use.  
Third, other than the fact that insurance status and coverage can impact both AET 
access and use behaviors, we found that individual level potential access such as 
socioeconomic and geographical factors can exert significant influences on the receipt 
of AET but not on AET adherence and persistence. In fact, AET adherence and 
persistence may still be matters of medication-related characteristics. Appalachian 
breast cancer patients who travelled longer to receive cancer care were significantly 
less likely to receive guideline-recommended AET. And, patients who lived in 
Pennsylvania were more likely to get access to guideline-recommended AET than those 
who did not, which also supplemented the findings from previous studies of superior 
breast cancer screening and treatment use in Pennsylvania compared with other 
Appalachian states.5,63 These findings may imply significant geographic variations of 
adjuvant treatment use in Appalachia, which may be crucial for resource allocation and 
leverage in such a largely rural and economically distressed region with limited 
resources available. On the other hand, non-adherence and early discontinuation with 
AET may be more driven by factors such as drug-related adverse effects. For instance, 
we found that pain may be an important factor causing AI non-adherence and non-
persistence. We primarily assessed symptomatic, common side effects associated with 
AET, but rare, severe adverse effects or fear of these side effects may also relate to 
patient use behaviors of AET. The importance of treatment choice and medication-
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related factors may have some implications for helping design the mechanism of 
effective interventions to improve AET use behaviors in Appalachia.  
Finally, we identified significantly positive influences of AET adherence and persistence 
on overall survival among Appalachian breast cancer survivors. Along with the findings 
among patients in other regions,122,137 our confidence is further increased concerning 
the positive link between AET adherence/persistence and overall survival among HR-
positive, non-metastatic breast cancer. Although the current literature, including this 
study, does not have adequate sample size and follow-up time to identify the effects of 
AET adherence and persistence on other direct cancer outcomes such as breast cancer 
recurrence and breast-cancer-specific survival, existing evidence still suggests the 
benefits of improving AET adherence and persistence in achieving more marginal gains 
in cancer survival among breast cancer survivors. 
 
6.2 Study implications 
Our results showed the value of improving AET adherence and persistence in benefiting 
survival and the unsatisfactory AET use outcomes in Appalachia, which implies the 
importance of ensuring appropriate use of AET to potentially reduce breast cancer 
mortality disparities that continuously exist in this region. However, developing 
evidence-based interventions to directly advance AET use behaviors is a continuous 
challenge for breast cancer survivorship care.178–180 To our knowledge, there has been 
no effective intervention available to promote AHT utilization and use behaviors. Our 
study findings may help build on the current knowledge of the potentially effective 
intervention strategies for this purpose. We found that patient access to and utilization 
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of AET may be largely attributable to logistical barriers in Appalachia, which implies that 
an intervention aiming to reduce access barriers and disparities in underserved regions 
may work. Patient navigation, which has played a critical role in cancer care, was 
originally proposed as a means of improving timely access to screening, follow-up, 
diagnosis, and treatment in underserved populations.181 The patient navigator is a 
specially trained person (e.g., healthcare professional, social worker, trained lay person, 
etc.) whose fundamental role is to assess and reduce barriers to care. Traditional 
patient navigation models focus on instrumental or informational support or reducing 
logistical barriers associated with areas such as finance, insurance, transportation, 
coordination, and communication with healthcare providers.182 However, the well-
established patient navigation model in cancer care has been successfully applied to 
various aspects of the breast cancer disease trajectory, but not to medication 
adherence.183 According to our findings that AET adherence and persistence were 
significantly influenced by medication-related factors such as drug-related side effects, 
we feel an important component targeting medication management may be missing in 
current patient navigation models in breast cancer care. Adding Medication Therapy 
Management (MTM) services to the patient navigation model may be an effective 
solution to this challenge. MTM refers to the medical services provided by pharmacists 
or qualified providers to optimize therapeutic outcomes via improving medication use. 
184,185 It has been shown to reduce non-adherence and healthcare expenditures across 
various chronic diseases.186 Core elements of MTM services in this model may 
include187: 1) medication therapy reviews (e.g., assessing patients’ medication use 
behaviors, identifying potential drug-related issues); 2) a personal medication record 
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(e.g., medication reconciliation); 3) a medication related action plan (e.g., identifying 
barriers to and facilitators of AET adherence, encourage patients to make family 
members get involved in the treatment process); 4) intervention and referral (e.g., 
offering informational or technical support for AET use, referring patients to medication 
assistance programs); and 5) documentation and follow-up (e.g., documenting the 
services and communicating to patients’ other health care providers, following up with 
patients at a regular basis if needed). The target population of the MTM component may 
be those breast cancer survivors who had poor AET adherence/persistence or other 
medication-related issues. One important targeted strategy worth noting in the MTM 
component is to monitor and manage AET-associated side effects. Alleviating the 
symptomatic side effects (e.g., vasomotor symptoms, musculoskeletal pain) through 
both provider management and patient self-management may help patients adhere to 
and persist with AET. Close monitoring is warranted for severe side effects (e.g., 
endometrial cancer and thromboembolism that are associated with tamoxifen, 
cardiovascular disease, and osteoporosis for AIs). Another important targeted strategy 
as part of patient navigator responsibilities is to help patients, especially elderly patients, 
choose a drug plan that could minimize out-of-pocket costs to reduce barriers to AET 
use. Although we found that insurance status and coverage were highly related to AET 
access and use, there is still significant room to improve in patient decision making in 
choosing optimal insurance benefits.116,188–190 Navigators may help them better 
understand their prescription drug plans and find the one that could minimize out-of-
pocket costs based on the individual patient’s situation. 
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6.3 Testing the conceptual model  
The conceptual model we proposed and tested was based on the Donabedian’s 
structure-process-outcome framework141, Andersen’s behavioral model for health 
service use142,143 and an extension of the Andersen’s model proposed by Pam Short 
and Roger Anderson (unpublished work), Hendren and colleagues’ cancer health 
disparity model,144 and the findings of published empirical work regarding AET 
medication use. In light of our results, constructs from the Andersen’s model such as 
predisposing factors (e.g., marital status and geographic residence) and enabling 
factors (e.g., travel time to receive care and dual Medicaid and Medicare eligibility) were 
related to the receipt of guideline-recommended AET. In other words, Appalachian 
breast cancer patients with superior individual level potential access were more likely to 
get access to appropriate adjuvant treatments. On the other hand, AET adherence and 
persistence were primarily associated with medication-specific characteristics such as 
side effects and drug costs. We did not find significant impacts of system-level potential 
access and realized access (facility/provider characteristics and care coordination) on 
AET utilization, adherence and persistence. We also identified the positive associations 
between AET adherence/persistence and overall survival. Overall, the conceptual 
model was generally informative and appropriate to guide the analyses of this study, but 
incorporating more psycho-behavioral factors may advance the prediction of AET use 
behaviors. Additionally, this study was not able to test several important constructs in 
the Hendren and colleagues’ cancer health disparities model144  such as patients’ 
medical and medication knowledge/beliefs, patient activation, and providers’ cultural 
competency, which warrants future research efforts. 
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6.4 Study limitations 
Next, the main limitations of the study are briefly reiterated. First, the retrospective 
claims study design prevented causal inferences; the assumptions of using claims data 
to study medication use behaviors may not always hold in reality, which may induce 
potential measurement errors or bias. In addition, the Medicare Part D claims data we 
used may also have some limitations. For instance, when patients were in the coverage 
gap, they might obtain AET from other sources than Medicare Part D, which may not be 
captured in our dataset. In addition, patients with dual eligibility may receive additional 
subsidies from their Medicaid programs to help with their out-of-pocket money, which 
were not able to be included in our calculation of out-of-pocket drug costs. Second, 
because of limited data accessibility and availability, we were not able to include some 
important, detailed information in our analyses, such as individual-level educational 
attainment and household income, treatment facility location, prescriber’s information, 
pharmacy type, accurate drug indications, and drugs used in the hospice setting. Third, 
the limited sample size and length of follow-up time may refrain us from detecting 
significant differences in some variables. For this reason, we were not able to assess 
the effects of AET adherence/persistence on some other direct breast cancer outcomes 
such as breast-cancer-specific survival. Lastly, the generalization of our results may be 
limited to Medicare enrollees living in Appalachia who are slightly older than the typical 
breast cancer population. 
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6.5 Future research and overall conclusion 
Based on the current literature, including this study, we find that the following areas may 
be warranted for future research: 1) the role of different healthcare plans on AET access 
and use behaviors; 2) geographic variations of AET use in Appalachia; 3) the effects of 
AET adherence/persistence in a long run, in a general breast cancer population with all 
age groups, on different health outcomes including breast cancer recurrence and 
survival, as well as patient-centered outcomes such as health-related quality of life 
(HRQoL). 
In conclusion, despite the significant survival benefits from AET use and adherence 
among breast cancer survivors with positive HR, the prevalence of receiving guideline-
recommended AET as well as its adherence and persistence is unacceptably low in 
Appalachia. Interventions that combine logistical barrier reduction and medication 
management may be effective to improve AET use in this population. 
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APPENDIX A 
Exemption from the Institution Review Board (IRB) regulation 
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APPENDIX B 
Centers for Medicare and Medicaid services (CMS) data use agreement  
 
 
 
 129 
 
APPENDIX C1 
Manuscript 1: testing the interactions in the multivariate logistic regression 
models of receiving guideline-recommended adjuvant endocrine therapy (AET) 
 
Model 1: Interaction between the 
state of residence and county 
economic status 
Odds Ratio 
(95% CI) 
Model 2: Interaction 
between the state of 
residence and HPSA 
Odds Ratio (95% 
CI) 
ARC's county economic status  HPSA designation  
          Distressed 1.13 (0.66, 1.93)           In the HPSA 0.48 (0.25, 0.94)* 
          Not distressed  Reference           Not in the HPSA Reference 
State   State   
          PA   1.58 (1.04, 2.40)*           PA   0.38 (0.12, 1.23) 
          Other states Reference           Other states Reference 
State × county economic status  1.05 (0.05, 21.36)  State × HPSA designation 4.60 (1.42, 14.81)* 
Notes:  
1. 95% CI = 95% confidence interval, ARC = Appalachian Regional Commission, HPSA = Health 
Professional Shortage Area 
2. *p < 0.05 
3. Covariates in these models included: county-level educational attainment (percentages of persons with 
less than high school education and at least a bachelor's degree), urban or rural geographic residence, 
county-level infant and cancer mortality rates, age at diagnosis, marital status, four quartiles of annual 
median household income (at the census block group level), dual Medicare and Medicaid eligibility 
indicator, average travel time from the patient to the three closes mammography centers, breast cancer 
stage, tumor size, lymph nodal status, patients’ comorbidities, treatment facility’s Commission on Cancer 
(CoC) accreditation status, the provider’s specialty and graduation year, the number of breast-cancer-
related follow-up visits, and timeliness of primary treatment initiation. 
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APPENDIX C2 
Manuscript 1: sensitivity analysis results from the multilevel mixed effect logistic 
regression of receiving guideline-recommended adjuvant endocrine therapy (AET) 
 
Variable Guideline-recommended 
AET 
 Coefficient (95% CI) 
Percentage of less than high school graduate among persons 
aged 25 and over (%) 
 0.03 (-0.02, 0.08) 
Percentage of at least a bachelor's degree among persons aged 
25 and over (%) 
 0.01 (-0.03, 0.04) 
Infant death rate per 1,000 births -0.19 (-0.40, 0.01) 
Annual age-adjusted, cancer-related death rate per 100,000 
population 
 0.002 (-0.009, 0.014) 
Average travel time to the three closest mammography centers 
(minute) 
-0.02 (-0.04, 0.0003) 
Baseline Charlson Comorbidity Index (CCI)  -0.09 (-0.23, 0.05) 
Baseline number of hospitalizations   0.02 (-0.13, 0.17) 
No. of breast cancer related follow-up visits -0.001 (-0.06, 0.06) 
ARC's county economic status  
            Distressed  Reference 
            At risk -0.55 (-1.27, 0.17) 
            Others -0.41 (-1.25, 0.42) 
Urban-rural classification  
            Metropolitan       -0.20 (-0.61, 0.20) 
            Non-metropolitan Reference 
Health Professional Shortage Area (HPSA) designation   
            Entirely within a HPSA Reference 
            Partially within in a HPSA -0.13 (-0.63, 0.36) 
            Not within a HPSA  0.11 (-0.55, 0.76) 
Age at diagnosis  
            <65 -0.28 (-0.91, 0.35) 
              65 to 74 Reference 
              75 to 84   0.10 (-0.22, 0.42) 
             ≥ 85  0.07 (-0.44, 0.59) 
Marital status  
          Married -0.49 (-0.80, -0.18)** 
          Not married Reference 
Annual median household income, quartile  
          Low Reference 
          Second  0.01 (-0.40, 0.42) 
          Third  0.12 (-0.28, 0.53) 
          High -0.04 (-0.46, 0.39) 
Dual Medicare and Medicaid eligibility status  
          Dual eligible  1.43 (1.00, 1.87)** 
          Medicare only  Reference 
Stage   
          Stage I  0.30 (-0.62, 1.22) 
          Stage II  0.14 (-0.42, 0.70) 
          Stage III Reference 
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Variable Guideline-recommended 
AET 
 Coefficient (95% CI) 
Tumor size   
         <1cm  Reference 
           1-2cm   0.20 (-0.17, 0.58) 
         >2cm  -0.05 (-0.70, 0.59) 
           Unknown -0.88 (-2.26, 0.49) 
Lymph nodal status  
           Negative Reference 
           Positive  0.18 (-0.36, 0.72) 
Commission on Cancer (CoC) accreditation  
           Yes -0.14 (-0.47, 0.20) 
           No Reference 
           Unknown -0.52 (-1.43, 0.39) 
Provider’s specialty  
           Oncologist 0.17 (-0.17, 0.52) 
           General practitioner Reference 
           Others 0.07 (-0.37, 0.51) 
Provider’s graduation year  
           Before 1980 -0.08 (-0.40, 0.24) 
           1980s Reference 
           After 1989 0.05 (-0.34, 0.44) 
Breast cancer surgery type  
           Breast conserving surgery (BCS) Reference 
           Mastectomy 0.15 (-0.20, 0.50) 
Radiation therapy  
           Yes 0.17 (-0.19, 0.54) 
           No Reference 
Chemotherapy  
           Yes 0.06 (-0.23, 0.36) 
           No Reference 
Timeliness of primary treatment initiation   
           Timely treatment (surgery within 60 days) Reference 
           Delayed treatment (surgery beyond 60 days) -0.15 (-0.73, 0.43) 
95% CI = 95% confidence interval, ARC = Appalachian Regional Commission 
**p < 0.01 
Likelihood ratio test (vs. logistic regression):  =0.88, p = 0.17 
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APPENDIX D1 
Manuscript 2: predictors of adherence to aromatase inhibitors (AI): multivariate 
logistic regression (N = 319) 
 
Variable Adherence to AI, Odds Ratio (95% CI) 
Percentage of at least a bachelor's degree among 
persons aged 25 and over (%) 
1.01 (0.97, 1.06) 
Infant death rate per 1,000 births 1.21 (0.54, 2.70) 
Annual age-adjusted, cancer-related death rate per 
100,000 population 
1.00 (0.99, 1.02) 
Baseline Charlson Comorbidity Index (CCI)  1.08 (0.80, 1.48) 
Average monthly out-of-pocket costs (US dollar) 0.994 (0.990, 0.998)** 
Health Professional Shortage Area (HPSA) designation   
            Whole county in HPSA Reference 
            Part county in HPSA 0.74 (0.26, 2.12) 
            Not in HPSA 0.73 (0.20, 2.57) 
State   
          KY 0.42 (0.12, 1.52) 
          NC 0.17 (0.02, 1.58) 
          OH 0.72 (0.29, 1.79) 
          PA Reference 
Dual Medicare and Medicaid eligibility status  
          Dual-eligible 0.96 (0.41, 2.25) 
          Medicare-only  Reference 
Catastrophic coverage indicator  
          Yes  3.99 (1.86, 8.56)** 
          No Reference 
Lymph nodal status  
           Negative Reference 
           Positive  1.75 (0.92, 3.33) 
Commission on Cancer (CoC) accreditation  
           Yes 0.73 (0.39, 1.37) 
           No Reference 
Provider specialty  
           Oncology 1.54 (0.83, 2.84) 
           General practitioner Reference 
           Other 0.79 (0.34, 1.82) 
Breast cancer surgery type  
           Mastectomy Reference 
           Breast conserving surgery (BCS) + radiation 0.56 (0.28, 1.10) 
           BCS, no radiation 0.57 (0.28, 1.19) 
Use of bisphosphonates  
           Yes 1.51 (0.77, 2.98) 
           No Reference 
Use of pain medications  
           Yes 0.41 (0.18, 0.93)* 
           No Reference 
 95% CI = 95% confidence interval        
 *p < 0.05 **p < 0.01 
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APPENDIX D2 
Manuscript 2: factors associated with discontinuation of aromatase inhibitors 
(AI): Cox proportional hazards (PH) model, stratified by the provider’s specialty 
and the patient’s dual eligibility status (N = 319) 
 
Variable AET discontinuation, Hazard Ratio (95% CI) 
Percentage of at least a bachelor's degree among 
persons aged 25 and over (%) 
0.98 (0.95, 1.02) 
Infant death rate per 1,000 births 1.27 (1.01, 1.59)* 
Annual age-adjusted, cancer-related death rate per 
100,000 population 
0.997 (0.986, 1.008) 
 
Baseline Charlson Comorbidity Index (CCI)  1.02 (0.81, 1.29) 
Age at diagnosis   
            <65 0.66 (0.22, 2.02) 
              65 to 74 Reference 
              75 to 84  1.20 (0.77, 1.87) 
             ≥ 85 0.98 (0.48, 2.02) 
Marital status  
          Married 1.17 (0.76, 1.82) 
          Not married Reference 
Annual median household income (US Dollar), 
quartile 
 
          Low ($9,768 - $31,408.5) Reference 
          Second ($31,408.5 - $ 41,552) 1.09 (0.60, 1.96) 
          Third  ($41,552 - $51,577.5) 0.97 (0.53, 1.78) 
          High ($51,577.5 - $15,0625) 0.99 (0.53, 1.84) 
Catastrophic coverage indicator  
          Yes  0.49 (0.27, 0.88)* 
          No Reference 
Lymph nodal status  
           Negative Reference 
           Positive  0.69 (0.41, 1.16) 
Commission on Cancer (CoC) accreditation  
           Yes 1.14 (0.66, 1.94) 
           No Reference 
Facility beds  
           <100 beds 1.04 (0.51, 2.15) 
          100-199 beds 0.57 (0.31, 1.04) 
           >=200 beds Reference 
Breast cancer surgery type  
           Mastectomy Reference 
           Breast conserving surgery (BCS) + radiation 1.22 (0.72, 2.07) 
           BCS, no radiation 1.45 (0.85, 2.47) 
Use of bisphosphonates  
           Yes 0.72 (0.42, 1.23) 
           No Reference 
Use of pain medications  
           Yes 1.92 (0.98, 3.75) 
           No Reference 
95% CI = 95% confidence interval 
*p < 0.05 
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APPENDIX D3 
Manuscript 2: predictors of adherence to tamoxifen: multivariate logistic 
regression (N = 80) 
 
Variable Adherence to AI, Odds Ratio (95% CI) 
Percentage of at least a bachelor's degree among 
persons aged 25 and over (%) 
0.85 (0.72, 1.01) 
Infant death rate per 1,000 births 0.58 (0.14, 2.41) 
Annual age-adjusted, cancer-related death rate per 
100,000 population 
1.04 (0.99, 1.10) 
Baseline Charlson Comorbidity Index (CCI)  1.70 (0.73, 3.96) 
Average monthly out-of-pocket costs (US dollar) 0.999 (0.978, 1.020) 
Health Professional Shortage Area (HPSA) designation   
            Whole county in HPSA Reference 
            Part county in HPSA 11.19 (0.13, 964.68) 
            Not in HPSA 12.66 (0.17, 939.63) 
State   
          KY 0.15 (0.002, 10.36) 
          NC 154.95 (0.51, 47266.84) 
          OH 0.12 (0.008, 2.02) 
          PA Reference 
Dual Medicare and Medicaid eligibility status  
          Dual-eligible 2.59 (0.07, 90.00) 
          Medicare-only  Reference 
Catastrophic coverage indicator  
          Yes  1.83 (0.17, 19.67) 
          No Reference 
Lymph nodal status  
           Negative Reference 
           Positive  0.06 (0.001, 2.75) 
Commission on Cancer (CoC) accreditation  
           Yes 4.97 (0.54, 45.53) 
           No Reference 
Provider specialty  
           Oncology 0.21 (0.02, 1.88) 
           General practitioner Reference 
           Other 0.11 (0.02, 0.72)* 
Breast cancer surgery type  
           Mastectomy Reference 
           Breast conserving surgery (BCS) + radiation 0.61 (0.02, 23.18) 
           BCS, no radiation 0.27 (0.01, 6.96) 
Use of bisphosphonates  
           Yes 0.39 (0.05, 3.14) 
           No Reference 
Use of pain medications  
           Yes 0.16 (0.02, 1.32) 
           No Reference 
 95% CI = 95% confidence interval        
 *p < 0.05  
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APPENDIX D4 
Manuscript 2: factors associated with discontinuation of tamoxifen: Cox 
proportional hazards (PH) model, stratified by the provider’s specialty and the 
patient’s dual eligibility status (N = 80) 
 
Variable AET discontinuation, Hazard Ratio (95% CI) 
Percentage of at least a bachelor's degree among 
persons aged 25 and over (%) 
1.12 (0.97, 1.30) 
Infant death rate per 1,000 births 0.48 (0.16, 1.42) 
Annual age-adjusted, cancer-related death rate per 
100,000 population 
1.06 (0.96, 1.16) 
 
Baseline Charlson Comorbidity Index (CCI)  3.96 (0.63, 24.93) 
Age at diagnosis   
            <65  
              65 to 74 Reference 
              75 to 84  0.02 (0.0002, 1.56) 
             ≥ 85 0.11 (0.0009, 13.82) 
Marital status  
          Married 0.86 (0.04, 16.42) 
          Not married Reference 
Annual median household income (US Dollar), 
quartile 
 
          Low ($9,768 - $31,408.5) Reference 
          Second ($31,408.5 - $ 41,552) 0.83 (0.01, 46.55) 
          Third  ($41,552 - $51,577.5) 3.48 (0.11, 106.64) 
          High ($51,577.5 - $15,0625)  
Catastrophic coverage indicator  
          Yes  2.39 (0.03, 190.23) 
          No Reference 
Lymph nodal status  
           Negative Reference 
           Positive  2.57 (0.03, 192.30) 
Commission on Cancer (CoC) accreditation  
           Yes 2.02 (0.19, 21.83) 
           No Reference 
Facility beds  
           <100 beds 4.86 (0.23, 103.64) 
          100-199 beds 1.06 (0.03, 36.05) 
           >=200 beds Reference 
Breast cancer surgery type  
           Mastectomy Reference 
           Breast conserving surgery (BCS) + radiation 1.22 (0.72, 2.07) 
           BCS, no radiation 1.45 (0.85, 2.47) 
Use of bisphosphonates  
           Yes  
           No Reference 
Use of pain medications  
           Yes 0.54 (0.007, 40.15) 
           No Reference 
95% CI = 95% confidence interval 
*p < 0.05, **p < 0.01 
Note that we did not present the results in a very small cell or with an extremely large standard deviation.  
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APPENDIX D5 
Manuscript 2: sensitivity analyses of predictors of adherence to adjuvant 
endocrine therapy (AET): multivariate logistic regression (N = 428) 
 
Variable Adherence to AI, Odds Ratio (95% CI) 
 0.6 cut-off point 0.7 cut-off point 0.9 cut-off point 
Percentage of at least a bachelor's degree 
among persons aged 25 and over (%) 
0.96 (0.92, 1.01) 0.97 (0.93, 1.02) 1.01 (0.97, 1.04) 
Infant death rate per 1,000 births 0.80 (0.44, 1.46) 1.09 (0.62, 1.92) 1.37 (0.84, 2.21) 
Annual age-adjusted, cancer-related death 
rate per 100,000 population 
1.01 (0.99, 1.02) 1.01 (0.99, 1.02) 1.00 (0.99, 1.02)  
Baseline Charlson Comorbidity Index 
(CCI)  
0.94 (0.69, 1.27) 0.96 (0.72, 1.28) 1.00 (0.78, 1.26) 
Average monthly out-of-pocket costs (US 
dollar) 
0.999 (0.994, 1.004) 0.997 (0.992, 1.001) 0.999 (0.995, 1.003) 
Health Professional Shortage Area (HPSA) 
designation  
   
            Whole county in HPSA Reference Reference Reference 
            Part county in HPSA 1.56 (0.58, 4.19) 1.14 (0.46, 2.84) 1.00 (0.46, 2.18) 
            Not in HPSA 1.06 (0.31, 3.64) 0.93 (0.30, 2.86) 1.42 (0.54, 3.78) 
State     
          KY 0.36 (0.11, 1.18) 0.36 (0.12, 1.10) 0.58 (0.22, 1.52) 
          NC 1.36 (0.19, 9.67) 0.44 (0.07, 2.67) 0.29 (0.06, 1.33) 
          OH 0.59 (0.24, 1.46) 0.51 (0.23, 1.17) 0.92 (0.45, 1.84) 
          PA Reference Reference Reference 
Dual Medicare and Medicaid eligibility 
status 
   
          Dual-eligible 0.99 (0.44, 2.22) 0.88 (0.42, 1.86) 1.26 (0.69, 2.33) 
          Medicare-only  Reference Reference Reference 
Catastrophic coverage indicator    
          Yes  3.95 (1.63, 9.60)** 5.24 (2.30, 11.92)** 2.93 (1.66, 5.20)** 
          No Reference Reference Reference 
Lymph nodal status    
           Negative Reference Reference Reference 
           Positive  1.34 (0.66, 2.72) 1.40 (0.75, 2.63) 1.40 (0.84, 2.32) 
Commission on Cancer (CoC) 
accreditation 
   
           Yes 1.40 (0.76, 2.61) 1.07 (0.60, 1.90) 0.89 (0.55, 1.43) 
           No Reference Reference Reference 
Provider specialty    
           Oncology 1.38 (0.71, 2.68) 1.31 (0.71, 2.42) 0.95 (0.58, 1.58) 
           General practitioner Reference Reference Reference 
           Other 1.63 (0.63, 4.20) 0.83 (0.38, 1.85) 0.36 (0.18, 0.73)** 
Breast cancer surgery type    
           Mastectomy Reference Reference Reference 
           Breast conserving surgery (BCS) + 
radiation 
0.65 (0.31, 1.36) 0.97 (0.50, 1.88) 0.78 (0.44, 1.35) 
           BCS, no radiation 0.64 (0.32, 1.31) 0.80 (0.42, 1.52) 0.49 (0.29, 0.84)* 
Use of bisphosphonates    
           Yes 1.14 (0.57, 2.27) 1.19 (0.63, 2.25) 1.38 (0.83, 2.32) 
           No Reference Reference Reference 
Use of pain medications    
           Yes 0.47 (0.20, 1.10) 0.53 (0.24, 1.19) 0.41 (0.19, 0.87)* 
           No Reference Reference Reference 
AET drug class    
          Tamoxifen 2.16 (1.00, 4.68)* 2.80 (1.35, 5.82)** 3.22 (1.77, 5.84)** 
          Aromatase inhibitor (AI) Reference Reference Reference 
          Switching between two drug classes 2.31 (0.64, 8.36)  2.50 (0.80, 7.83) 1.48 (0.63, 3.45) 
 95% CI = 95% confidence interval        
 *p < 0.05 **p < 0.01 
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APPENDIX D6 
Manuscript 2: sensitivity analyses of factors associated with discontinuation of 
adjuvant endocrine therapy, using the 90-day medication fill gap (N = 428) 
Variable AET discontinuation using the 90-day 
medication fill gap, Hazard Ratio (95% CI) 
Percentage of at least a bachelor's degree among 
persons aged 25 and over (%) 
0.98 (0.94, 1.01) 
 
Infant death rate per 1,000 births 1.22 (0.98, 1.52) 
Annual age-adjusted, cancer-related death rate per 
100,000 population 
0.99 (0.98, 1.005) 
 
Baseline Charlson Comorbidity Index (CCI)  0.95 (0.74, 1.21) 
Age at diagnosis   
            <65 0.65 (0.21, 1.98) 
              65 to 74 Reference 
              75 to 84  0.97 (0.59, 1.61) 
             ≥ 85 1.29 (0.63, 2.62) 
Marital status  
          Married 0.98 (0.60, 1.60) 
          Not married Reference 
Annual median household income (US Dollar), 
quartile 
 
          Low ($9,768 - $31,408.5) Reference 
          Second ($31,408.5 - $ 41,552) 0.92 (0.47, 1.78) 
          Third  ($41,552 - $51,577.5) 0.82 (0.42, 1.60) 
          High ($51,577.5 - $15,0625) 1.44 (0.74, 2.78) 
Catastrophic coverage indicator  
          Yes  0.60 (0.32, 1.14) 
          No Reference 
Lymph nodal status  
           Negative Reference 
           Positive  0.47 (0.26, 0.87)* 
Commission on Cancer (CoC) accreditation  
           Yes 0.97 (0.55, 1.72) 
           No Reference 
Facility beds  
           <100 beds 0.95 (0.45, 2.01) 
          100-199 beds 0.65 (0.35, 1.22) 
           >=200 beds Reference 
Breast cancer surgery type  
           Mastectomy Reference 
           Breast conserving surgery (BCS) + radiation 0.97 (0.54, 1.74) 
           BCS, no radiation 1.25 (0.71, 2.20) 
Use of bisphosphonates  
           Yes 0.62 (0.34, 1.13) 
           No Reference 
Use of pain medications  
           Yes 1.94 (1.01, 3.73)* 
           No Reference 
AET drug class  
          Tamoxifen 0.43 (0.22, 0.83)* 
          Aromatase inhibitor (AI) Reference 
          Switching between two drug classes 0.43 (0.15, 1.24) 
95% CI = 95% confidence interval, *p < 0.05 
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APPENDIX D7 
Manuscript 2: selected results of sensitivity analyses of the associations between 
adjuvant endocrine therapy (AET) non-adherence/non-persistence and all-cause 
mortality, using Cox proportional hazards (PH) models (N = 428) 
 
Model  Variable  All-cause mortality, Hazard 
Ratio (95% CI) 
Model 1 Non-adherence to AET, defined as MPR < 0.6 6.32 (1.61, 24.86)** 
Model 2 Non-adherence to AET, defined as MPR < 0.7 9.53 (2.19, 41.41)** 
Model 3 Non-adherence to AET, defined as MPR < 0.9 8.60 (1.92, 38.66)** 
Model 4 Non-persistence with AET, defined as at least 
90-day medication fill gap 
3.71 (1.03, 13.37)* 
95% CI = 95% confidence interval, MPR = Medication Possession Ratio 
*p < 0.05, **p < 0.01 
Covariates in these models included: age at diagnosis, marital status, marital status, dual 
Medicare and Medicaid eligibility indicator, breast cancer stage, tumor size, treatment facility’s 
Commission on Cancer (CoC) accreditation status, facility beds, type of breast cancer surgery, 
baseline number of hospitalizations,  the number of breast-cancer-related follow-up visits, and 
no. of unique prescription drugs co-administered. 
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